Methods for the treatment of testosterone-dependent disorders
Leflutrozole administration addresses the limitations of current treatments for male infertility and hypogonadism by improving sperm quality and DNA integrity, providing a fertility-friendly alternative.
Patent Information
- Application Number
- PCT/IB2026/054868
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-23
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Current therapies for male infertility and testosterone deficiency, such as testosterone replacement therapy, can adversely affect spermatogenesis and are not suitable for men desiring fertility, while existing treatments for hypogonadotropic hypogonadism are limited and ineffective.
Administering a therapeutically effective amount of leflutrozole periodically to treat male infertility and hypogonadotropic hypogonadism, improving sperm quality and integrity by measuring improvements in total sperm count, concentration, motility, morphology, and DNA fragmentation index.
Leflutrozole treatment enhances sperm quality and maintains or improves sperm DNA integrity, offering a viable option for men with hypogonadism seeking fertility without the adverse effects of traditional therapies.
Smart Images

Figure IMGF000014_0001 
Figure IMGF000031_0001_TABLE 
Figure IMGF000032_0001_TABLE
Abstract
Description
[0001] ATTORNEY DOCKET NO: 51835-010WO3
[0002] METHODS FOR THE TREATMENT OF TESTOSTERONE-DEPENDENT DISORDERS Field of the Invention
[0003] The invention relates to the therapeutic treatment of disorders of the male reproductive system, including male infertility and hypogonadotropic hypogonadism, among others, as well as the reduction of symptoms associated therewith.
[0004] Background of the Invention
[0005] Male hypogonadism is a condition characterized by serum testosterone concentrations below the normal range for young, healthy men, along with associated symptoms, such as impaired spermatogenesis. In the United States, the prevalence of low serum testosterone levels has recently been reported to be about 21 .5% in men of 21-39 years of age, with the prevalence increasing six-fold in those with signs of central obesity. It is considered that an important mechanism for the hypogonadotropic hypogonadism associated with obesity is the impact of increased estradiol levels in obese men which exerts negative feedback on pituitary release of gonadotropins. With increasing adipose tissue in men, there is an increased aromatase-dependent conversion of testosterone to estradiol, resulting in an excess of estradiol to testosterone levels.
[0006] Current therapies for male infertility and testosterone deficiency are limited. Most hypogonadal men are treated with intramuscular injections of testosterone every 2 to 4 weeks, typically requiring a visit to a health care provider. Some men choose testosterone gels or patches that are usually applied daily. Administration of exogenous testosterone in men can adversely affect spermatogenesis via suppression of the hypothalamic-pituitary axis. Because of this, testosterone replacement therapy (TRT) is not indicated in men with hypogonadism desiring fertility. Treatment options for hypogonadal men desiring fertility are limited to injectable urinary human chorionic gonadotropin (hCG) products to achieve normal serum testosterone levels, with the use of injectable recombinant follicle-stimulating hormone (FSH) to induce spermatogenesis in infertile men with primary and secondary hypogonadism.
[0007] In light of the disadvantages associated with existing treatment options for male infertility, hypogonadotropic hypogonadism, and testosterone deficiency, there exists a need for new and improved therapies for treating testosterone-dependent disorders.
[0008] Summary of the Invention
[0009] The present disclosure features methods of treating male infertility in a subject (e.g., a human patient) in need thereof. The methods include administering to the patient a therapeutically effective amount leflutrozole. The methods of the disclosure can be used to treat male infertility resulting from, for example, male hypogonadotropic hypogonadism, among other conditions described herein.
[0010] Efficacious treatment may be evaluated by monitoring for improvements in sperm quality and / or increases in total sperm quantity and testosterone levels, among other parameters disclosed in the sections that follow.
[0011] In a first aspect, the disclosure features a method of treating male infertility in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following administration,ATTORNEY DOCKET NO: 51835-010WO3
[0012] e.g., by measuring an improvement in the patient’s sperm quality after the administering. In some embodiments, the patient additionally maintains or improves integrity of sperm DNA after the administering.
[0013] In another aspect, the disclosure features a method of treating male infertility in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by measuring an improvement in sperm quality, as well as a maintenance or improvement in the integrity of sperm DNA after the administering.
[0014] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by measuring an improvement in sperm quality, as well as a maintenance or improvement in the integrity of sperm DNA after the administering.
[0015] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by measuring an improvement in sperm quality, as well as a maintenance or improvement in the integrity of sperm DNA after the administering.
[0016] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by measuring an improvement in sperm quality, as well as a maintenance or improvement in the integrity of sperm DNA after the administering.
[0017] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by measuring an improvement in sperm quality, as well as a maintenance or improvement in the integrity of sperm DNA after the administering.
[0018] In another aspect, the disclosure features a method of treating male infertility in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
[0019] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement inATTORNEY DOCKET NO: 51835-010WO3
[0020] sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
[0021] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
[0022] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
[0023] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
[0024] In another aspect, the disclosure features a method of treating male infertility in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change inATTORNEY DOCKET NO: 51835-010WO3
[0025] the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0026] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0027] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0028] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of aATTORNEY DOCKET NO: 51835-010WO3
[0029] semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0030] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0031] In another aspect, the disclosure features a method of treating male infertility in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient maintains or improves sperm quality. In some embodiments, the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0032] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient maintains or improves sperm quality. In some embodiments, the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0033] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient maintains or improves sperm quality. In some embodiments, the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to aATTORNEY DOCKET NO: 51835-010WO3
[0034] measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0035] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering. In some embodiments, the patient maintains or improves sperm quality. In some embodiments, the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0036] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient maintains or improves sperm quality, wherein the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0037] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in total motile sperm count (TMSC) relative to a measurement of the patient’s TMSC obtained prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0038] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in total sperm count relative to a measurement of the patient’s total sperm count obtained prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient followingATTORNEY DOCKET NO: 51835-010WO3
[0039] the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0040] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in sperm concentration relative to a measurement of the patient’s sperm concentration obtained prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0041] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in sperm motility relative to a measurement of the patient’s sperm motility obtained prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0042] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in the percentage of sperm that have a normal sperm morphology relative to a measurement of the patient’s sperm morphology obtained prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0043] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount ofATTORNEY DOCKET NO: 51835-010WO3
[0044] leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in semen volume relative to a measurement of the patient’s semen volume obtained prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
[0045] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm DNA integrity as measured by a decrease in DNA fragmentation index (DFI).
[0046] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof by periodically administering to the patient a therapeutically effective amount of leflutrozole. In some embodiments, therapeutic efficacy may be assessed following the administering, e.g., by determining that the patient exhibits an improvement in sperm DNA integrity as measured by a decrease in DNA fragmentation index (DFI).
[0047] In another aspect, the disclosure features a method of treating male infertility in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0048] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0049] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality andATTORNEY DOCKET NO: 51835-010WO3
[0050] integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0051] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0052] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0053] In another aspect, the disclosure features a method of treating male infertility in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0054] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof by a) periodically administering to the patient aATTORNEY DOCKET NO: 51835-010WO3
[0055] therapeutically effective amount of lef lutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively, and c) continuing the periodic administration of a therapeutically effective amount of lef lutrozole.
[0056] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of lef lutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively, and c) continuing the periodic administration of a therapeutically effective amount of lef lutrozole.
[0057] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of lefl utrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.ATTORNEY DOCKET NO: 51835-010WO3
[0058] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of lefl utrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA. In some embodiments, the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering. In some embodiments, the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering. In some embodiments, a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0059] In another aspect, the disclosure features a method of treating male infertility in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0060] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0061] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0062] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.ATTORNEY DOCKET NO: 51835-010WO3
[0063] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof by a) periodically administering to the patient a therapeutically effective amount of lefl utrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering, and c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
[0064] In some embodiments, the decrease in DNA fragmentation index (DFI) is 5% or greater. In some embodiments, following administration the patient exhibits an improvement in sperm quality as measured by an increase in total motile sperm count (TMSC). In some embodiments, the increase in TMSC is greater than 5 million. In some embodiments, following administration the patient exhibits an improvement in sperm quality as measured by any one of changes in total sperm count, sperm concentration, sperm motility, normal sperm morphology or semen volume. In some embodiments, following administration the patient exhibits an improvement in sperm quality as measured by increases in total sperm count. In some embodiments, following administration the patient exhibits an improvement in sperm quality as measured by increases in sperm concentration. In some embodiments, following administration the patient exhibits an improvement in sperm quality as measured by changes in sperm motility. In some embodiments, following administration the patient exhibits an improvement in sperm quality as measured by changes in sperm morphology. In some embodiments, following administration the patient exhibits an improvement in sperm quality as measured by increases in semen volume.
[0065] In another aspect, the disclosure features a method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in total motile sperm count (TMSC) as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.
[0066] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in TMSC as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.
[0067] In a further aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in TMSC as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.
[0068] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in TMSC as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.ATTORNEY DOCKET NO: 51835-010WO3
[0069] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in TMSC as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.
[0070] In a further aspect, the disclosure features a method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
[0071] In another aspect, the disclosure features a method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
[0072] In another aspect, the disclosure features a method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
[0073] In another aspect, the disclosure features a method of improving testicular function in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
[0074] In another aspect, the disclosure features a method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
[0075] In some embodiments, the patient exhibits a normalization of total serum testosterone levels, such as a normalization to a total serum testosterone level of from about 300 ng / dL to about 1000 ng / dL.
[0076] In some embodiments, the therapeutically effective amount of leflutrozole is a dose ranging from about 0.025 mg to about 2.5 mg. In some embodiments, the therapeutically effective amount of leflutrozole is any one of 0.05 mg, 0.1 mg, 0.3 mg per dose. In some embodiments, the periodic administration involves one dose of leflutrozole per week. In some embodiments, the therapeutically effective amount of leflutrozole is administered orally. In some embodiments, the therapeutically effective amount of leflutrozole is administered as a hard gelatine capsule.
[0077] In some embodiments, the patient has a total motile sperm count (TMSC) less than 20 million determined prior to treatment. In some embodiments, the patient has a total motile sperm count (TMSC) greater than 1 million determined prior to treatment. In some embodiments, the patient is an adult man aged 18-65 years. In some embodiments, the patient has serum total testosteroneATTORNEY DOCKET NO: 51835-010WO3
[0078] concentration level below about 300 ng / dL prior to treatment. In some embodiments, the patient has serum follicle stimulating hormone (FSH) level 1 -12 I U / L prior to treatment. In some embodiments, the patient has serum sex hormone binding globulin (SHGB) level above the lower limit of normal (LLN) prior to treatment. In some embodiments, the patient has serum estradiol (E2) level above the LLN prior to treatment. In some embodiments, the patient has serum luteinizing hormone (LH) level below the LLN prior to treatment.
[0079] In some embodiments, the patient does not have known history of osteoporosis or fragility fractures prior to treatment. In some embodiments, the patient does not have known history of thromboembolic disease prior to treatment. In some embodiments, the patient did not have myocardial infarction or unstable angina within 6 months prior to treatment. In some embodiments, the patient did not have coronary artery bypass surgery, balloon angioplasty, percutaneous coronary intervention or carotid revascularization procedure within 6 months prior to treatment. In some embodiments, the patient did not have uncontrolled hypertension within 3 months prior to treatment. In some embodiments, the patient did not have significant cardiac arrhythmia within 6 months prior to treatment. In some embodiments, the patient did not have advanced ischemic heart disease within 6 months prior to treatment. In some embodiments, the patient did not have stroke or transient ischemic attack within 6 months prior to treatment.
[0080] Brief Description of the Figures
[0081] FIG. 1 is a schematic of the clinical trial described in Example 1 , below. Briefly, patients undergoing the study described in Example 1 may be administered either (1) placebo control or (2) lef lutrozole at a dosage of from 0.05 mg to 0.3 mg, once weekly, for a period of 16 weeks. The patients may then be monitored for a post-treatment follow-up period of four weeks. Additional details as to the indicia of therapeutic efficacy of leflutrozole and the procedures used for monitoring each patient are described in Example 1 , below.
[0082] Detailed Description of the Invention
[0083] The present disclosure relates to the compound leflutrozole (4-[(4-cyanophenyl)-fluoro-(1 ,2,4-triazol-1 -yl)methyl]benzonitrile) and its various medical applications. The chemical structure of leflutrozole is:
[0084]
[0085] Leflutrozole
[0086] Without being limited by mechanism, leflutrozole acts as an aromatase inhibitor, thereby inhibiting conversion of androgens into estrogens (for example, the aromatization of testosterone to estradiol).
[0087] The methods of the present disclosure can be used to treat a variety of testosteronedependent disorders, including male hypogonadotropic hypogonadism and infertility, among others.ATTORNEY DOCKET NO: 51835-010WO3
[0088] For example, using the methods described herein, a patient, such as a male human patient, may be administered leflutrozole in order to not only treat the cause of the testosterone-dependent pathology, but also to alleviate one or more symptoms associated these conditions. Exemplary diseases that are induced by decreased testosterone production, and that can be treated using the compositions and methods described herein, include, without limitation, male infertility, male hypogonadotropic hypogonadism, and various other male reproductive disorders.
[0089] Leflutrozole is a selective, non-steroidal, and reversible aromatase inhibitor which blocks the aromatase enzyme (CYP19), thereby restricting the conversion of testosterone to estradiol and androstenedione to estrone. The administration of leflutrozole is expected to be useful in the treatment of obesity-associated hypogonadotropic hypogonadism and male infertility, as these subjects have increased estradiol levels resulting from overexpressed aromatase in adipose tissues. The higher aromatase activity results in decreased testosterone levels in these subjects, that ultimately may result in reductions in fertility.
[0090] Leflutrozole is a treatment option that targets the primary pathophysiology of infertility that can arise in some men. Using the compositions and methods described herein, leflutrozole can normalize serum testosterone levels and reduce estradiol levels, which, in turn, may enhance the production of luteinizing (LH) and follicle-stimulating hormone (FSH) by the pituitary gland, increasing serum concentrations of LH and FSH. Subsequently, this may stimulate testicular function, increasing testosterone production and ultimately spermatogenesis.
[0091] The sections that follow describe exemplary methods of treatment of testosterone-dependent and male reproductive disorders that utilize leflutrozole and compositions of the disclosure.
[0092] Definitions
[0093] As used herein the singular forms "a," "an," and, "the" include plural reference unless the context clearly dictates otherwise.
[0094] The term “about” when modifying a numerical value or range herein includes normal variation encountered in the field, and includes plus or minus 1-10% (e.g., 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%) of the numerical value or end points of the numerical range. Thus, a value of about 10 includes all numerical values from 9 to 11. All numerical ranges described herein include the endpoints of the range unless otherwise noted, and all numerical values in-between the end points, to the first significant digit.
[0095] As used herein, the term “administering” means to provide a compound or other therapy, remedy, or treatment such that an individual internalizes the compound or therapy. Administering a compound is the process by which a subject becomes exposed to a therapeutic compound or composition of the disclosure.
[0096] As used herein, the term “compound” is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted, unless otherwise specified. All compounds may be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or, can be isolated and / or generated in anhydrous form. For example, the term “solvate,” as used herein, means a compound or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces.ATTORNEY DOCKET NO: 51835-010WO3
[0097] Exemplary solvents are volatile, non-toxic, and / or acceptable for administration to humans in trace amounts. The term “hydrate” as used herein means a compound or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. Alternatively, the term “anhydrous” refers to a compound that excludes all solvent molecules, including water. The term “compound” is also meant to be agnostic as to how the compound is formed, be it synthetically or biologically.
[0098] As used herein, the term “hypogonadism” refers to a group of disorders that are indicated by improper or absent levels of sex hormones due to malfunction in the sex glands, organs, or tissues. Hypogonadisms may develop as a result of lifestyle factors, such as excess body weight (e.g., being overweight or obese (BMI > 25 kg / m2)), circumstances surrounding fasting, or abstaining from food, or of weight loss potentially associated with stress are also implicated in hypogonadisms. Reduction in sex hormones may also be caused by injury to the respective organs or glands, genetic factors, the progression to menopause in females, other therapeutic treatments (such as those for cancers), or as a byproduct of autoimmune disorders or viral infections. A hypogonadism may be primary or secondary. A primary hypogonadism refers to conditions in which the subject has malfunctioning sex organs, e.g., the testes in a male, such that the subject no longer appropriately produces sex hormones. A primary hypogonadism may be diagnosed by persistently low testosterone levels that coincide with above-normal luteinizing hormone (LH) levels (or follicle stimulating hormone / FSH). A secondary hypogonadism refers to the subset of subjects that have a malfunctioning hypothalamus or pituitary gland, and hormone production is not regulated due to insufficient chemical signaling.
[0099] Secondary hypogonadisms (e.g., hypogonadotropic), such as those caused by obesity, may be diagnosed by both a low sperm count and either normal or low levels of LH or FSH. In some embodiments, the hypogonadism is not associated with intrinsic damage to the subject’s hypothalamus or pituitary gland.
[0100] As used herein, the terms “in need of treatment” and “in need thereof” when referring to treatment, are used interchangeably to mean a judgment made by a caregiver (e.g., physician, nurse, or nurse practitioner in the case of humans; veterinarian in the case of animals, including non-human mammals) that an individual or animal requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of a caregiver’s expertise, but that includes the knowledge that the individual or animal is ill, or will become ill, as the result of a disease, condition or disorder that is treatable by the compounds of the disclosure. Accordingly, the compounds of the disclosure can be used in a protective or preventive manner; or compounds of the disclosure can be used to alleviate, inhibit, or ameliorate the disease, condition, or disorder.
[0101] As used herein, the term “pharmaceutical composition” refers to a specific composition comprising at least one active ingredient, including but not limited to, solids, crystalline forms (e.g., an anhydrous form, a hydrate, or another solvate), and compounds of the present disclosure, whereby the composition is amenable to administration for a specified, efficacious outcome in a subject (e.g., a mammal, such as a human subject). A pharmaceutical composition typically includes both an active substance and one or more pharmaceutically acceptable excipients that improve the pharmacological properties of the active substance. The excipients included may also improve pharmacokineticATTORNEY DOCKET NO: 51835-010WO3
[0102] properties in order to improve variables such as absorption, excretion, drug release, tissue exposure, metabolism of the active substance, or any other property suitable for improving administration. Excipients may also be included in order to improve the processability of a compound or composition of the disclosure. For example, inclusion of certain excipients may improve the ability of the active compound to become formulated as a powder due to the addition of certain glidants or binders. Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan.
[0103] As used herein, the term “prescribing” means to order, authorize, or recommend the use of a drug or other therapy, remedy, or treatment. In some embodiments, a health care provider orally advises, recommends, or authorizes the use of a compound, dosage regimen, or other treatment to an individual. The health care provider may or may not provide a written prescription for the compound, dosage regimen, or treatment. Further, the health care provider may or may not provide the compound or treatment to the individual. For example, the health care provider can advise the individual where to obtain the compound without providing the compound. In some embodiments, a health care provider can provide a written prescription for the compound, dosage regimen, or treatment to the individual. A prescription can be written on paper or recorded on electronic media. In addition, a prescription can be called in (oral) or faxed in (written) to a pharmacy or a dispensary. In some embodiments, a sample of the compound or treatment is given to the individual. As used herein, giving a sample of a compound constitutes an implicit prescription for the compound. Different health care systems around the world use different methods for prescribing and administering compounds or treatments, and these methods are encompassed by the disclosure herein. A health care provider can include, for example, a physician, nurse, nurse practitioner, or other health care professional who can prescribe or administer compounds (or composition) for the disorders disclosed herein. In addition, a health care provider can include anyone who can recommend, prescribe, administer, or prevent an individual from receiving a compound or composition, including, for example, an insurance provider.
[0104] As used herein, the terms “prevent,” “preventing,” and “prevention” refer to the elimination or reduction of the risk of occurrence or onset of one or more symptoms associated with a particular disorder. For example, the terms “prevent,” “preventing,” and “prevention” can refer to the administration of therapy on a prophylactic basis to an individual who is at risk of manifesting at least one symptom of a disorder but who has not yet done so. Such individuals can be identified on the basis of risk factors that are known to correlate with the subsequent occurrence of the disease, such as the presence of a biomarker. Alternatively, prophylaxis can be administered without the explicit, prior identification of a risk factor. Successful prophylaxis can be evaluated by observing, among other indicia, a delay in the onset of at least one episode and / or symptom of a disorder (e.g., a testosterone-dependent disease described herein).
[0105] As used herein, the term “therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, or human that is being sought by an individual, researcher, veterinarian, medical doctor, or other clinician or caregiver, which can include one or more of the following:ATTORNEY DOCKET NO: 51835-010WO3
[0106] 1. preventing the disorder, for example, preventing a disease, condition, or disorder in an individual who may be predisposed to the disease, condition, or disorder but does not yet experience or display the relevant pathology or symptomatology;
[0107] 2. inhibiting the disorder, for example, inhibiting a disease, condition, or disorder in an individual who is experiencing or displaying the relevant pathology or symptomatology (i.e. , arresting further development of the pathology and / or symptomatology); and
[0108] 3. ameliorating the disorder, for example, ameliorating a disease, condition, or disorder in an individual who is experiencing or displaying the relevant pathology or symptomatology (i.e., reversing the pathology and / or symptomatology).
[0109] As used herein, the term “male infertility” refers to the inability of a male subject to establish a successful pregnancy, as evaluated by the capacity of the subject to endogenously produce one or more sperm cells capable of fertilizing a mature ovum in a manner that results in the generation of a zygote and, ultimately, a growing embryo. For example, a couple consisting of a male and a female may be characterized as experiencing fertility difficulties if no pregnancy occurs following a minimum of at least one year of regular unprotected vaginal intercourse. Male infertility may result from a variety of factors, including medical conditions, lifestyle choices, and environmental influences, among others. One key cause of male infertility is male hypogonadism, which is characterized by below-normal male sex hormone levels. Reduction in sex hormones may also be caused by injury to the respective organs or glands, genetic factors, other therapeutic treatments such as those for cancers, or as a byproduct of autoimmune disorders or viral infections. Low testosterone production may disrupt spermatogenesis, which is dependent on maintenance of high levels of intratesticular testosterone by the Leydig cells, as well as of FSH stimulation of Sertoli cells.
[0110] As used herein, the term “aromatase inhibitor” refers to a compound that inhibits the function of enzymes known as aromatases e.g., CYP19 (aromatase P450), that play key roles in the biosynthesis and conversion of various hormones, e.g., the conversion of testosterone to estradiol. The relative excess of estradiol can feedback to the hypothalamic pituitary axis, suppressing gonadotropin (FSH and LH) secretion, thereby reducing testicular testosterone production and spermatogenesis. Without being limited by mechanism, aromatase inhibitors, such as leflutrozole, may normalize serum testosterone levels and reduce estradiol levels, which, in turn, may enhance the production of LH and FSH by the pituitary gland, thereby increasing serum concentrations of LH and FSH. Subsequently, this increase in LH and FSH may stimulate testicular function, increasing testosterone production and, ultimately, spermatogenesis.
[0111] As used herein, the term “total motile sperm count (TMSC)” refers to a measurement of sperm quality that is calculated by multiplying the semen volume (mL) by sperm concentration (million / mL) and the percentage of motile sperm (%). TMSC is a composite parameter of sperm concentration, motility and semen volume, which is considered an indicator of semen quality. Recent studies have underscored TMSC as a reliable predictor of pregnancy in medically assisted reproduction, such as intrauterine insemination (IUI). Additionally, TMSC has been linked to both pregnancy rates and time to conception in natural conception cycles. Increasing TMSC is considered a good treatment strategy for couples with male factor infertility, as it enables: 1) the use of IUI orATTORNEY DOCKET NO: 51835-010WO3
[0112] natural conception rather than more advanced procedures such as in vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI); 2) enhanced success rates of IUI treatment cycles and the likelihood of natural conception; and 3) a reduction in the burden on the female partner by focusing treatment strategies directly on the male.
[0113] As used herein, the term “DNA fragmentation index (DFI)” refers to a measurement of the amount of DNA damage in the DNA of sperm cells. This metric is described, e.g., in Bjorndahl L, Kirkman Brown J. The sixth edition of the WHO Laboratory Manual for the examination and Processing of Human Semen: ensuring quality and standardization in basic examination of human ejaculates. Fertil Steril. (2022) ; 117:246-51 , the disclosure of which is incorporated herein by reference. It will be appreciated that sperm cells with fragmented DNA are less likely to successfully fertilize a mature ovum.
[0114] As used herein, the term “sperm quality” refers to any attribute of a sperm and / or semen sample that relate to male fertility, for example, as evidenced by likelihood of successfully fertilizing a mature ovum. Measurements of sperm quality include, but are not limited to, TMSC, DFI, total sperm count (TSC), sperm concentration, sperm motility, normal sperm morphology, and semen volume. As used herein, the term “sperm concentration” refers to number of sperm cells present per milliliter of male ejaculate. A normal, healthy range is between 20 million to 300 million per milliliter. As used herein, the terms “total sperm count” and “TSC” refer to the total number of sperm cells present in an entire semen sample, which is calculated from sperm concentration and semen volume. As used herein, the term “sperm mobility” refers to the movement and speed of sperm cells. As used herein, the term “normal sperm morphology” refers to the size and shape of sperm. As used herein, the term “semen volume” refers to the total volume, typically listed in milliliters, of male ejaculate.
[0115] As used herein, the term “oligospermia” refers to the condition of a subject who displays a low sperm count. The sperm count may be considered lower than normal if sperm count is under, e.g., 20 x 106 / mL, or under 15 x 106 / mL of the composition of semen. A complete loss of sperm production is referred to as azoospermia, and subjects presenting such condition are also contemplated to be within the scope of the disclosed methods of treatment.
[0116] As used herein, the term “systolic blood pressure” refers to the amount of pressure experienced by the arteries while the heart is beating, typically measured in millimeter of mercury (mmHg). Healthy systolic blood pressures are typically below 120 mmHg, and any systolic blood pressure above 130 mmHg is considered hypertension, with hypertension severity increasing with pressure measurement.
[0117] As used herein, the term “diastolic blood pressure” refers to the amount of pressure experienced by the arteries while the heart is resting in between heart beats. Healthy diastolic blood pressures are typically below 80 mmHg, and any diastolic blood pressure above 80 mmHg is typically considered hypertension, with hypertension severity increasing with pressure measurement. Both systolic and diastolic blood pressure are critical cardiovascular health measurements. Hypertension can lead to or contribute to serious cardiovascular health problems, including heart attack and stroke.
[0118] As used herein, the terms “normalization of total serum testosterone levels” or “serum total testosterone concentration level” refer to serum testosterone levels between 300 to 1000 ng / dL 10.4ATTORNEY DOCKET NO: 51835-010WO3
[0119] to 35 nmol / L),. Normalized serum testosterone levels may be defined as between 300 to 1000 ng / dL (10.4 to 35 nmol / L), and anything outside this range may be considered abnormal (e.g., “low” being < 300 ng / dL and “high” being > 1000 ng / dL).
[0120] As used herein, the term “estradiol” and “E2” refer to an estrogen steroid hormone. High levels of estradiol is associated with hypogonadotropic hypogonadism, particularly hypogonadotropic hypogonadism associated with obesity. As used herein, the term “luteinizing hormone” and “LH” refer to a hormone produced by gonadotropic cells of the anterior pituitary gland. In males, LH stimulates Leydig cell production of testosterone and acts synergistically with follicle-stimulating hormone (FSH). As used herein, the terms “follicle stimulating hormone” and “FSH” refer to a gonadotropin hormone, that is synthesized and secreted by the gonadotropic cells of the anterior pituitary gland. FSH plays a pivotal role in regulating development, growth, pubertal maturation, and reproductive processes of the body. FSH and LH work together in the reproductive system. It is considered that the main mechanism for the hypogonadotropic hypogonadism associated with obesity is the impact of increased estradiol levels in obese men which exerts negative feedback on pituitary release of gonadotropins. With increasing adipose tissue in men, there is an increased aromatase-dependent conversion of testosterone to estradiol, resulting in an excess of estradiol to testosterone levels. Thus, the relative higher estradiol levels have a negative effect on the pituitary release of FSH and LH which would be expected to compromise testicular function, reducing testicular production of testosterone and spermatogenesis, and thereby result in abnormal semen parameters which compromise fertility potential. High estrogen levels in combination with low androgen levels have also been shown to impair spermatogenesis in animals.
[0121] As used herein, the term “sex hormone binding globulin” and “SHBG” refer to a glycoprotein that binds to androgens and estrogens.
[0122] As used herein, the terms “lower limit of normal” and “LLN” refer to values that correspond with the lowest values that are still considered normal, healthy values. Measurements above the LLN are within or above a normal range.
[0123] As used herein, the terms “upper limit of normal” and “ULN” refer to values that correspond with the highest values that are still considered normal, healthy values. Measurements below the ULN are within or below a normal range.
[0124] As used herein, the terms “treat,” “treating,” and “treatment” refer to the administration of therapy to an individual who already manifests, or who has previously manifested, at least one symptom of a disease, disorder, condition, dependence, or behavior. For example, “treating” can include any of the following with respect to a disease, disorder, condition, dependence, or behavior: alleviating, abating, ameliorating, improving, inhibiting (e.g., arresting the development), relieving, or causing regression. “Treating” can also include treating the symptoms, preventing additional symptoms, preventing the underlying physiological causes of the symptoms, or stopping the symptoms (either prophylactically and / or therapeutically) of a disease, disorder, condition, dependence, or behavior. For example, the term “treating” in reference to a disorder means a reduction in severity of one or more symptoms associated with a particular disorder. Therefore, treating a disorder does not necessarily mean a reduction in severity of all symptoms associated withATTORNEY DOCKET NO: 51835-010WO3
[0125] a disorder and does not necessarily mean a complete reduction in the severity of one or more symptoms associated with a disorder. For example, successful treatment in the indication of disease infertility may be indicated by change in level of testosterone from less than 300 ng / dL to between 300 ng / dL and 1000 ng / dL.
[0126] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. In addition, subcombinations of uses and medical indications listed in the embodiments describing such uses and medical indications described herein, are also specifically embraced by the present invention just as if each subcombination of uses and medical indications was individually and explicitly recited herein.
[0127] Pharmaceutical Compositions and Routes of Administration
[0128] Oral Administration as a Solid or Capsule
[0129] Leflutrozole may be prepared as a solid suitable for oral administration. Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tableting lubricants and disintegrants may be used in tablets and capsules for oral administration. Alternatively, the oral preparations may be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. In the case of dry powders suitable for reconstitution in liquid vehicles, additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives and flavorings and colorants may be added to the liquid preparations.
[0130] Leflutrozole hard gelatin capsules are an immediate release dosage form for oral administration. The excipients used to prepare leflutrozole hard gelatin capsules are lactose monohydrate, microcrystalline cellulose, corn starch, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide. All the excipients of the leflutrozole hard gelatin capsules comply with the requirements of the applicable compendial monographs (Ph.Eur., NF). Lactose is pharmaceutical grade derived from milk sourced from healthy animals in the same conditions as milk collected for human consumption. The lactose is prepared with the use of calf rennet and no other material of ruminant origin. The magnesium stearate is of vegetable origin. The composition of the capsule is gelatin, titanium dioxide (E171 , CI77891 ) and iron oxide, red (E172, CI77491 ). The hard gelatin capsule shell is a non-compendial component with all its individual constituents meeting the requirements of the pharmacopoeias and / or international standards.
[0131] Liquid Formulations and Suspensions for Oral Administration
[0132] Leflutrozole can be used in the preparation of liquid formulations, such as in the form of a solution, suspension, or emulsion. Liquid preparations for oral administration may be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives and flavorings and colorants may be added to the liquid preparations. Formulations suitable for oral administration can consist of (a) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (b) powders; (c) liquid solutions,ATTORNEY DOCKET NO: 51835-010WO3
[0133] such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Preferred are solid oral dosage forms such as capsule forms, tablet forms, and powder forms. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and cornstarch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art. In some instances, the composition is administered as a dry powder that is reconstituted as a liquid prior to administration to the subject, thereby forming a solution or suspension.
[0134] Topical Administration and Transdermal Patches
[0135] Topical pharmaceutical formulations, including those that are useful for transdermal drug release, are well-known to those of skill in the art and are suitable in the context of the invention for application to skin. Said pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by a transdermal patch. Transdermal patches dispense a drug at a controlled rate by presenting the drug for absorption in an efficient manner with minimal degradation of the drug. Typically, transdermal patches comprise an impermeable backing layer, a single pressure sensitive adhesive and a removable protective layer with a release liner. One of ordinary skill in the art will understand and appreciate the techniques appropriate for manufacturing a desired efficacious transdermal patch based upon the needs of the artisan. Topically applied compositions are generally in the form of liquids, creams, pastes, lotions and gels. Topical administration includes application to the oral mucosa, which includes the oral cavity, oral epithelium, palate, gingival, and the nasal mucosa. In some embodiments, the composition contains at least leflutrozole and a suitable vehicle or carrier. It may also contain other components, such as an anti-irritant. The carrier can be a liquid, solid or semisolid. In embodiments, the composition is an aqueous solution. Alternatively, the composition can be a dispersion, emulsion, gel, lotion or cream vehicle for the various components. In one embodiment, the primary vehicle is water or a biocompatible solvent that is substantially neutral or that has been rendered substantially neutral. The liquid vehicle can include other materials, such as buffers, alcohols, glycerin, and mineral oils with various emulsifiers or dispersing agents as known in the art to obtain the desired pH, consistency and viscosity. It is possible that the compositions can be produced as solids, such as powders or granules. The solids can be applied directly or dissolved in water or a biocompatible solvent prior to use to form a solution that is substantially neutral or that has beenATTORNEY DOCKET NO: 51835-010WO3
[0136] rendered substantially neutral and that can then be applied to the target site. In embodiments of the invention, the vehicle for topical application to the skin can include water, buffered solutions, various alcohols, glycols such as glycerin, lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin and silicone-based materials.
[0137] Injectable Solutions
[0138] Parenteral (e.g., injectable) dosage forms may be prepared by dissolving the compound of the disclosure in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampule. The solutions may then be administered to a subject to treat a disease or condition by injection into a blood vessel or to the target site, as appropriate.
[0139] Exemplary Dosing Regimens for Leflutrozole
[0140] Dosage Amounts
[0141] In one aspect, provided herein are dosage amounts and regiments for administration of leflutrozole in appropriate amounts to treat a disorder in a subject. The dose when using the compounds of the present disclosure can vary within limits and as is customary and is known to the physician, it is to be tailored to the individual conditions in each individual case. It depends, for example, on the nature and severity of the illness to be treated, on the condition of the subject, on the compound employed or on whether an acute or chronic disease state is treated or prophylaxis conducted or on whether further active compounds are administered in addition to the compounds of the present disclosure. Representative doses of the present disclosure include, but not limited to, from 0.001 to 5 mg. Depending on the individual and as deemed appropriate from the subject's physician or caregiver it may be necessary to deviate upward or downward from the doses described herein. For example, the dose administered to the subject may be 0.001 mg (1 pg), 0.01 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg, 3.0 mg, 4.0 mg, or 5 mg. Accordingly, the acceptable amount of leflutrozole to be administered may be present in an amount from 0.001 mg to 5 mg in the composition, not accounting for the weight of pharmaceutically acceptable excipients that also are part of the composition. In some instances, smaller amounts may be administered or prepared from a single unit dose form.
[0142] The amount of active ingredient required for use in treatment will vary not only with the particular form selected but also with the route of administration, the nature of the condition being treated and the age and condition of the subject and will ultimately be at the discretion of the attendant physician or clinician. In general, one skilled in the art understands how to extrapolate in v / vodata obtained in a model system, typically an animal model, to another, such as a human. In some circumstances, these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weights, but rather incorporate a variety of factors.
[0143] Representative factors include the type, age, weight, sex, diet and medical condition of the subject, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, on whether an acute or chronic disease state is beingATTORNEY DOCKET NO: 51835-010WO3
[0144] treated or if prophylaxis conducted, or on whether further active compounds are administered that are incompatible with leflutrozole administration, such that the dose amounts administered to a subject may be reduced in order to mitigate the effects of simultaneous treatment of disorders unrelated to the present disclosure.
[0145] Dosage Regimens
[0146] In some cases, sustained treatment with leflutrozole is required in a subject on account of the reversibility of observed effects. The disease or condition to be treated may also be chronic, requiring repeated administration over several weeks, months, or years, or even for the entirety of the remainder of a subjects’ lifetime. In some embodiments, the dose amount administered to the subject is administered every week, every two weeks, every three weeks, every four weeks, every five weeks, every six weeks, every seven weeks, or every eight weeks. Alternatively, the dose may be administered every month. In some instances, the dose amount to be administered during a given dosing period may be administered in several smaller doses to total a desired target dose, depending on the needs of the subject. For example, a dose amount administered during a dosing period of one week provides a total amount of the leflutrozole will be administered during a one-week period, for instance a prescribed 0.3 mg dose administered weekly may sometimes be administered in the form of two separated 0.15 mg administrations during the one-week period. The two 0.15 mg administrations might occur once in the morning and once at night (e.g., twice in one day), such that the administration period comprises once twice daily / once weekly dosing. Alternatively, the first of two 0.15 mg administrations might occur on day 1 of the one-week administration period (7 days), and the second of two 0.15 mg administrations might occur on day 3. In such cases, the second 0.15 mg administration may occur on day 1 , day 2, day 3, day 4, day 5, day 6, or day 7 during a one-week administration period.
[0147] In some embodiments, the compound is administered according to a dosing regimen having a dosing periodicity selected from about one dose once weekly to about one dose once every month. However, the pharmaceutical compositions may also be formulated for administration at any frequency of administration, including once every 5 days, once every 3 days, once every 2 days, twice a day, three times a day, four times a day, five times a day, six times a day, eight times a day, every hour, or any greater frequency. In some embodiments, the compound is administered according to a dosing regimen having a dosing periodicity of one dose once weekly.
[0148] In some embodiments, the desired dose is administered as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete, loosely spaced administrations. If appropriate, depending on individual behavior, it may be necessary to deviate upward or downward from the daily dose indicated.
[0149] The dosage regimen for treating a disease condition with the compounds and / or compositions of this disclosure is selected in accordance with a variety of factors as cited above. Thus, the actual dosage regimen employed may vary widely and therefore may deviate from a preferred dosageATTORNEY DOCKET NO: 51835-010WO3
[0150] regimen and one skilled in the art will recognize that dosage and dosage regimen outside these typical ranges can be tested and, where appropriate, may be used in the methods of this disclosure.
[0151] Variable Dosing Adjusted by Titer
[0152] Many of the diseases or conditions to be treated in the disclosure may be monitored by phenotypic metabolites or biomarkers that serve as observable indicators as to the effectiveness of a given treatment. Accordingly, administration of the compounds or pharmaceutical compositions of the disclosure may be used in methods of treating disorders in which the subject is monitored for the expression of hormones, proteins, or other suitable molecules for measuring a desired treatment outcome as familiar to the skilled artisan. In some cases, the hypogonadism is not associated with intrinsic damage to the subject’s hypothalamus or pituitary gland. While receiving treatment, the dose amount of leflutrozole to be administered may be adjusted according to a response measurement of a biomarker in comparison to some previous measurement. A subject may require varied or steadily increasing doses to be administered in order to normalize serum testosterone levels, up to the dose that results in normalization. Normalized serum testosterone levels may be defined as between 300 to 1000 ng / dL (10.4 to 35 nmol / L), and anything outside this range may be considered abnormal (e.g., “low” being < 300 ng / dL and “high” being > 1000 ng / dL). Subjects displaying low serum testosterone may initially receive 0.1 mg of leflutrozole, but if such dose fails to restore serum testosterone to normal levels after 1 week, a second dose during the treatment period of 0.2 mg may be administered, and so on. An example of such an escalating dose to determine the appropriate dose for subject, one may administer 0.1 mg leflutrozole during week 1 of a treatment period to a subject with 100 ng / dL serum testosterone, 0.3 mg during week two of a treatment period where the same subject now measures at 250 ng / dL serum testosterone, and 1.0 mg during week three of a treatment period where the same subject now measures at 450 ng / dL serum testosterone. However, in the event that resulting serum testosterone becomes high following the 1.0 mg dose being administered to said subject, the dose may then be reduced back down to < 1.0 mg leflutrozole. For instance, if the aforementioned subject has a serum testosterone measurement of >1000 ng / dL following a 1.0 mg dose administration, the dose may be reduced to, for example, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, or 0.5 mg, as determined by a physician and the subject’s response to treatment.
[0153] In some instances, the compound is administered via a titration scheme. In some embodiments, the titration scheme comprises the up-titration of the dose, e.g., if the initial dose has an insufficient effect, until an optimized dose is administered. In some embodiments, the dose is up-titrated if the subject does not normalize testosterone levels or significantly increase FSH or LH after the first weeks of treatment. In some embodiments, the titration scheme comprises the down-titration of the dose, e.g., if the subject experiences side effects, until an optimized dose is administered. In some embodiments, the dose is down-titrated if the subject has an adverse effect on blood pressure, hematocrit, polycythemia, and the like.ATTORNEY DOCKET NO: 51835-010WO3
[0154] Methods of Treating Male Infertility and Other Testosterone-Dependent Conditions Infertility
[0155] The disclosure provides a method of treating diseases or disorders in a subject in need thereof, the treatment comprising administering a therapeutically effective amount of leflutrozole or a pharmaceutical composition of the disclosure. For instance, leflutrozole, serving as an aromatase inhibitor, can be used for the treatment of infertility. Thus, there are presented methods of treating infertility in a subject in need thereof, in which the method comprises administering an appropriate amount of leflutrozole. Infertility in male subjects may be caused by reductions in sperm count (e.g., oligospermia), semen quality, sperm motility, semen volume, testosterone levels, luteinizing hormone (LH), follicle stimulating hormone (FSH), or by elevated levels of estradiol in a subject that is associated with high body mass index (BMI, high being >25 kg / m2). Thus, the methods of treatment may be for treating infertility in an overweight or obese male subject. As a result of any of the methods of treatment, levels of biomarkers may become normalized after treatment in comparison to a baseline measurement. For instance, sperm count may be increased after initiating treatment with anhydrous leflutrozole, maintained for the duration of the treatment period or until treatment discontinues.
[0156] Hypogonadotropic Hypogonadism in Males
[0157] The disclosure describes, in part, methods of treating obesity-associated hypogonadotropic hypogonadism (OHH), such as in overweight or obese male subjects. In particular, overweight or obese men may suffer from overexpression of aromatase (CYP19) due to heightened presence of adipose tissue, where aromatase is highly expressed. Excess adipose tissue leads to overexpression aromatase and an associated increase in its measured activity, thus resulting in higher levels of estradiol in a subject. In males, the excess estradiol may feedback a hypothalamic pituitary axis, suppressing gonadotropic secretion and thereby suppressing testicular testosterone production and spermatogenesis. Severe obesity is associated with androgen deficiency in males. The consequences of testosterone deficiency in males may be decreased libido, decreased spontaneous erections (or erectile dysfunction), decreased fertility (infertility), loss of body hair and reduced shaving, low bone mineral density (BMD), increased risk of fractures, decreased muscle mass and strength, fatigue, or impacts on mood and cognition. Furthermore, metabolic abnormalities may result from androgen deficiencies, including but not limited to insulin resistance, glucose intolerance, and lipid abnormalities that may contribute to incidences of metabolic syndrome or cardiovascular disease. As the mechanism of aromatase activity is the conversion of androgens to estrogens, there is thus a need for the treatment of OHH males by inhibiting aromatase activity. Accordingly, leflutrozole (an aromatase inhibitor) may be administered for such purpose to normalize levels of testosterone in a subject.
[0158] In some cases, the diseases or disorder to be treated is hypogonadotropic hypogonadism (HH). In some embodiments, the hypogonadotropic hypogonadism may be obesity-associated. Thus, there is provided the treatment of OHH males by administration of leflutrozole or a pharmaceutical composition comprising leflutrozole. Some embodiments relate to the treatment of male subjects with total serum testosterone levels below 300 ng / dL and in need of increased testosterone levels. InATTORNEY DOCKET NO: 51835-010WO3
[0159] cases where the HH is obesity-associated, the subject may have a body-mass index (BMI) of > 30 kg / m2. However, HH may be present in non-obese subjects who are still understood to be within the scope of the methods of treatment as determined by serum testosterone levels and being characterized as overweight. Thus, subjects may have a BMI of 25 kg / m2or greater and are within the scope of the methods of the disclosure if they have sufficiently low serum testosterone levels. In some embodiments, the hypogonadism is not associated with intrinsic damage to the subject’s hypothalamus or pituitary gland.
[0160] In some embodiments, the method is a method of treating HH in a subject having a BMI of between 25 and 50 kg / m2. In some cases, the method is a method of treating HH in a subject having a serum testosterone of < 300 ng / dL. In some embodiments, the testosterone level is increased by at least 10% in comparison to the testosterone level prior to administration of any of the compounds or compositions of the disclosure. In some embodiments, the testosterone level of the subject becomes normalized following administration of the leflutrozole (e.g., is raised to between 300 and 1000 ng / dL). A sustained effect can be observed for as long as 12 weeks, until monitoring of the patient is discontinued, or until the end of the treatment period. An inverse effect may be observed for estradiol levels in a subject due to the reduction in aromatase activity that coincides with leflutrozole administration. Accordingly, there is also provided methods for reducing estradiol levels in a subject by administering leflutrozole, where the amount of estradiol decreases by between 25 and 55% as compared to prior to the first administration (e.g., prior to start of treatment, or baseline) during the treatment period. For example, estradiol levels measured in a subject may change from 26 ± 7.2 ng / L at baseline to 18.2 ± 9.6 by week 12 of the treatment period.
[0161] Some embodiments concern the production of luteinizing hormone (LH) or follicle-stimulating hormone (FSH). Both LH and FSH are glycoprotein hormones that act together to regulate the secretion of testosterone. LH stimulates the production of testosterone by action on Leydig cells, whereas FSH regulates the differentiation of spermatocytes and is critical to the initiation of spermatogenesis. Obese males may have dysregulated LH and FSH production on account of the increased aromatase activity causing a decrease in basal testosterone levels. The reduction in testosterone is associated with a decrease in the production of inhibins, proteins that in turn would downregulate FSH synthesis. Thus, a negative feedback loop develops where subjects experience reduced FSH levels and therefore cannot upregulate the production of testosterone in response to obesity-associated increases in aromatase activity. The two major hormones LH and FSH may be increased in production because of leflutrozole treatment, thus in turn increasing testosterone production and spermatogenesis. The disclosure therefore provides methods for increasing levels of luteinizing hormone in a subject in need thereof, wherein the method comprises administering an appropriate amount of leflutrozole. In some embodiments, the methods are for increasing levels of follicle stimulating hormone in a subject in need thereof, the method comprising administering leflutrozole. In some cases, the leflutrozole administered for increasing or decreasing the levels of a biomarker within a subject may be administered as a leflutrozole composition.
[0162] In some embodiments, the subject needs prevention or treatment of one or more disorders selected from metabolic syndrome, type II diabetes, obesity, cardiovascular disease, insulinATTORNEY DOCKET NO: 51835-010WO3
[0163] resistance, glucose intolerance and dyslipidemia. In some embodiments, the subject is in need of one or more of improved insulin sensitivity, improved glucose metabolism and an improved lipid profile.
[0164] In some embodiments, the subject is in need of the prevention or treatment of one or more disorders selected from the group consisting of decreased libido, decreased spontaneous erections, erectile dysfunction, decreased fertility, decreased spermatogenesis, decreased semen quality, loss of body hair, reduced shaving, lack of energy, fatigue, impaired cognition, depression, changes in mood, low bone mineral density, increased risk of fractures, decreased muscle mass, decreased muscle strength, increased abdominal fat mass and limited body performance capacity.
[0165] In some embodiments, the subject is in need of one or more of increased muscle mass and strength, a normalized body composition, a decrease in abdominal fat mass, an improved sexual function and desire, increased fertility and increased bone mineral density.
[0166] The subject may be experiencing one or more lowered levels of sexual function as a result of OHH symptoms. Such deficiencies in sexual function may be characterized by a low volume of semen, low spermatozoa count, low sperm concentration, reduced sperm motility, low total motile sperm count, or oligospermia.
[0167] Oligospermia is a symptom in OHH males that is characterized by low sperm count, typically being less than 15-20 million per milliliter of semen. In some embodiments, the subject has severe oligospermia (defined as <20 million per ejaculate). In some cases, the levels of inhibin B present in a subject increases by between 7-15 ng / L when treated with the compositions of the invention. Inhibin B is a biomarker that is reflective of decreases in estradiol levels, and thus increases in inhibin B levels are consistent with aromatase inhibition.
[0168] Other uses of the disclosed compounds and methods will become apparent to those skilled in the art based upon, inter alia, a review of this disclosure. As will be recognized, the steps of the methods of the present invention need not be performed any particular number of times or in any particular sequence. Additional objects, advantages and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are illustrative and not limiting.
[0169] Examples
[0170] The following examples are put forth so as to provide those of ordinary skill in the art with a description of how the methods described herein may be used and evaluated and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventor(s) regard as their invention.
[0171] Example 1. A Dose-Response Study Evaluating the Efficacy and Safety of leflutrozole on Testicular Function in Men with Hypogonadotropic Hypogonadism
[0172] In order to assess the ability of leflutrozole to treat infertile men with hypogonadotropic hypogonadism, the following study may be conducted: This sections that follow describe exemplary empirical endpoints, patient populations, and dosing parameters that may be used to evaluate the activity of leflutrozole in treating male infertility in a subject in need thereof.ATTORNEY DOCKET NO: 51835-010WO3
[0173] Objective
[0174] Primary objectives can include:
[0175] • To evaluate the dose-response relationship of 3 doses of leflutrozole (0.05, 0.1 , and 0.3 mg weekly) on semen quality.
[0176] Secondary objectives can include:
[0177] • To evaluate the efficacy of leflutrozole on improving semen quality.
[0178] • To evaluate the efficacy of leflutrozole on normalizing serum total testosterone levels.
[0179] • To evaluate the effect of leflutrozole in serum reproductive hormones.
[0180] • To characterize the pharmacokinetics (PK) of leflutrozole in plasma and exposure in semen.
[0181] • To evaluate the effect of leflutrozole on libido (sexual desire) and fatigue.
[0182] • To evaluate the safety profile of leflutrozole including adverse events, routine safety laboratory parameters and electrocardiogram (ECG).
[0183] • To evaluate the effect of leflutrozole on cardiometabolic parameters.
[0184] • To evaluate the effect of leflutrozole on bone turnover markers.
[0185] Exploratory objectives can include:
[0186] • To explore the relationship between body mass index (BMI) and leflutrozole levels in plasma and semen.
[0187] • To explore the plasma exposure relationship (PK / pharmacodynamics[PD]) of leflutrozole and serum reproductive hormone levels as well as semen concentrations and parameters. • To explore the relationship between serum reproductive hormone levels and changes of semen parameters.
[0188] • To explore the effect of leflutrozole on serum inflammatory markers.
[0189] Endpoints
[0190] Primary endpoints can include:
[0191] • Change in total motile sperm count (TMSC) after 16 weeks of treatment.
[0192] Secondary endpoints can include:
[0193] • Changes in total sperm count (TSC), sperm concentration, sperm motility, normal sperm morphology, and semen volume after 16 weeks of treatment.
[0194] • Percentage of participants with TMSC >5 million, >10 million, and >20 million after 16 weeks of treatment.
[0195] • Percentage of participants with a relative increase of >50%, >75% and >100% in TMSC after 16 weeks of treatment.
[0196] • Percentage of participants with sperm DNA fragmentation index (DFI) <15%, <25% and <30% after 16 weeks of treatment.
[0197] • Normalization of serum total testosterone levels (300-1000 ng / dL) in >75% of participants after 16 weeks of treatment.ATTORNEY DOCKET NO: 51835-010WO3
[0198] • Percentage of participants with normal serum total testosterone levels (300-1000 ng / dL) after 4, 8, 12 and 16 weeks of treatment.
[0199] • Changes in serum concentrations of total testosterone, free testosterone, bioavailable testosterone, sex hormone-binding globulin (SHBG), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, inhibin B, and total testosterone / estradiol ratio after 4, 8, 12 and 16 weeks of treatment.
[0200] • Plasma concentrations of lef I utrozole after 4, 8, 12 and 16 weeks of treatment.
[0201] • Semen concentrations of leflutrozole after 12 weeks of treatment.
[0202] • Changes in the libido subdomain scores of the Hypogonadism Impact of Symptoms Questionnaire Short Form (HIS-Q SF) after 4 and 16 weeks of treatment.
[0203] • Changes in the energy domain scores of the HIS-Q SF after 4 and 16 weeks of treatment. • Percentage of participants who overshoot testosterone (serum total testosterone >1500 ng / dL) at any time during the trial.
[0204] • Frequency and intensity of adverse events, including serious adverse events and adverse events leading to discontinuation.
[0205] • Changes in circulating levels of clinical chemistry and hematology parameters after 4, 8, 12 and 16 weeks of treatment.
[0206] • Changes in serum prostate-specific antigen (PSA) levels after 4, 8, 12 and 16 weeks of treatment.
[0207] • Changes in ECG parameters including PR interval, QT interval, corrected QT using Fridericia’s formula (QTcF) and QRS interval after 16 weeks of treatment.
[0208] • Changes in systolic and diastolic arterial blood pressure, and proportion of participants with systolic blood pressure >140 mmHg and diastolic pressure >90 mmHg, and proportion of participants with systolic blood pressure >160 mmHg and diastolic pressure >110 mmHg after 4, 8, 12 and 16 weeks of treatment.
[0209] • Changes in lipids (total cholesterol, low density lipoprotein [LDL] cholesterol, high density lipoprotein [HDL] cholesterol, and triglycerides) and in carbohydrate metabolism parameters (glycated hemoglobin [HbA1c], fasting glucose, fasting insulin, and homeostatic model assessment for insulin resistance [HOMA-IR]) after 16 weeks of treatment.
[0210] • Changes in serum C-terminal cross-linking telopeptide of type 1 collagen (s-CTx) and serum procollagen type 1 N propeptide (s-PINP) after 16 weeks of treatment.
[0211] Exploratory endpoints can include:
[0212] • Relationship between BMI and leflutrozole levels in plasma and semen throughout the trial.
[0213] • Dose-exposure relationship between plasma concentrations of leflutrozole and serum LH, FSH, total testosterone, free testosterone, bioavailable testosterone, estradiol, inhibin B, and total testosterone / estradiol ratio levels throughout the trial.
[0214] • Changes in serum reproductive hormones and plasma concentrations of leflutrozole from baseline to the end of the follow-up period and from week 16 to the end of the follow-up period.ATTORNEY DOCKET NO: 51835-010WO3
[0215] • Correlation between plasma and semen concentrations of leflutrozole after 12 weeks of treatment.
[0216] • Dose-exposure relationship between plasma concentrations of leflutrozole and semen parameters (e.g., TMSC, total sperm count, and sperm concentration) after 16 weeks of treatment.
[0217] • Correlation of absolute and relative changes in total testosterone levels, free testosterone levels, bioavailable testosterone levels, FSH levels, inhibin B levels, and total testosterone / estradiol ratio and semen parameters (e.g., TMSC, total sperm count, and sperm concentration) after 16 weeks of treatment.
[0218] • Changes in serum hs-CRP after 16 weeks of treatment and the end of the follow-up period.
[0219] Overall Design
[0220] This is a randomized, placebo-controlled, double-blind, parallel-group, dose-response, multicenter trial. The trial is designed to establish dose-response of oral leflutrozole 0.05 mg, 0.1 mg, and 0.3 mg weekly on improving semen parameters, and will also document the normalization of serum total testosterone in men with hypogonadotropic hypogonadism, as well as evaluate the efficacy and safety of leflutrozole compared to placebo. The primary endpoint is change in TMSC from baseline to week 16.
[0221] The trial is divided into three periods: 1 ) a screening period of up to 4 weeks, 2) a treatment period of 16 weeks with either leflutrozole 0.05 mg, 0.1 mg, 0.3 mg, or placebo weekly (randomization in a 1 :1 :1 :1 ratio), and 3) a follow-up period of 4 weeks. In addition, a phone call will be made to the participant 3 months after end of trial to inquire about potential pregnancy in a female partner.
[0222] Eligible participants will be men aged 18-49 years with a low TMSC across a spectrum ranging from mild to severe degrees of male factor infertility. Furthermore, participants will have a diagnosis of hypogonadotropic hypogonadism, as documented by low serum total testosterone concentrations in association with normal or low serum gonadotropin concentrations, and pathologies involving the pituitary gland or hypothalamus will be ruled out.
[0223] It is planned to randomize 200 participants, 50 per group, in order to achieve at least 43 participants per group who are evaluable for the primary endpoint. Participants will be stratified into two strata based on the TMSC at baseline according to severity: >1 to <10 million, and >10 million (if two semen samples are collected at screening, the average TMSC will be used for stratification).
[0224] Investigational Medicinal Products
[0225] Treatment Arm Drug Type Active Ingredient and Doses and Regimen Route of
[0226] Administration
[0227] Leflutrozole 0.05 mg Aromatase inhibitor Hard gelatine capsules One capsule of 0.05 containing 0.05 mg mg leflutrozole weekly leflutrozole for oral orally administration
[0228]
[0229] ATTORNEY DOCKET NO: 51835-010WO3
[0230] Leflutrozole 0.1 mg Aromatase inhibitor Hard gelatine capsules One capsule of 0.1 mg containing 0.1 mg leflutrozole weekly leflutrozole for oral orally administration
[0231] Leflutrozole 0.3 mg Aromatase inhibitor Hard gelatine capsules One capsule of 0.3 mg containing 0.3 mg leflutrozole weekly leflutrozole for oral orally administration
[0232] Placebo Placebo Hard gelatine capsules One capsule of containing placebo placebo weekly orally
[0233]
[0234] Capsules of placebo and different doses of leflutrozole will be indistinguishable from each other. All capsules will be taken orally by the participant with water on a weekly basis (±1 day from the time schedule of regular planned doses) at approximately the same time of the day.
[0235] Duration of Treatment
[0236] The treatment duration is 16 weeks.
[0237] Number of Participants
[0238] It is planned to randomize 200 participants, 50 per group, in order to achieve at least 43 participants per group who are evaluable for the primary endpoint.
[0239] Eligibility Criteria
[0240] Inclusion Criteria can include:
[0241] 1. Signed informed consent form (ICF) prior to any-related trial activity.
[0242] 2. Adult men aged 18-49 years (both inclusive).
[0243] 3. Fasting morning (before 10 AM) serum total testosterone concentration <300 ng / dL on two occasions, of which one sample must be at screening and the other sample must be at or within 24 months prior to screening.
[0244] 4. Serum SHBG above the lower limit of normal (LLN) (i.e., within or above normal range) at screening.
[0245] 5. Serum estradiol (E2) level above the LLN (i.e., within or above normal range) at screening.
[0246] 6. Serum LH level below the upper limit of normal (ULN) (i.e., within or below normal range) at screening.
[0247] 7. Serum FSH level 1 -12 I LJ / L at screening.
[0248] 8. TMSC >1 million and <20 million in two samples collected 2-3 days after sexual abstinence and at least 7 days apart, of which one sample must be at screening and the other sample must be at or within 12 months prior to screening. In case both samples are obtained at screening, the allowed TMSC of >1 million and <20 million applies to the average of the two samples.ATTORNEY DOCKET NO: 51835-010WO3
[0249] 9. Semen volume >1.0 mL in two samples collected 2-3 days after sexual abstinence and at least 7 days apart, of which one sample must be at screening and the other sample must be at or within 12 months prior to screening.
[0250] 10. Agreement on the part of the participant to follow the below precautions from the time of randomization to 4 months after the last dose of investigational medicinal product (IMP): a. Use barrier contraception (male condom) during vaginal intercourse with a female partner of childbearing potential and request the female to use an approved contraceptive method.
[0251] b. Use barrier protection (male condom) during non-vaginal sexual intercourse with a female partner of childbearing potential.
[0252] c. Refrain from donating blood or sperm, and from using sperm for medically assisted reproductive technologies with the female partner.
[0253] 11. Ability to understand and comply with the requirements of the protocol.
[0254] Exclusion Criteria can include:
[0255] 1. History of cryptorchidism, malignant or benign tumors of the testes, testicular torsion, testicular trauma requiring treatment, orchitis, or other primary lesions of the testis.
[0256] 2. Known history or presence of clinically visible varicocele (subclinical and Grades I and II are acceptable).
[0257] 3. Obstructive condition in the male reproductive tract, including any structural abnormalities of the vas deferens (unilateral or bilateral) at screening.
[0258] 4. Known chromosome abnormalities (e.g., Klinefelter syndrome or Y-chromosome microdeletion).
[0259] 5. Pituitary or hypothalamic disease as based on the following:
[0260] a. Current or history of hypothalamic or pituitary tumor.
[0261] b. Suspicion of hypothalamic or pituitary tumor based on a clinical or laboratory suspicion (e.g., symptoms or signs of tumor mass effect, unless there is documentation of a normal magnetic resonance imaging scan of pituitary and hypothalamus within 3 months before screening visit).
[0262] c. Suspicion of hypothalamic or pituitary conditions, which may contribute to hypogonadism (e.g., pituitary sarcoidosis, histiocytosis or tuberculosis).
[0263] 6. Prostate disease as confirmed by the presence of either of the following:
[0264] a. History of prostate cancer.
[0265] b. Elevated prostate-specific (PSA) levels >2.5 ng / mL at the screening assessment.
[0266] 7. Treatment with one or more of the following prescription drugs or over-the-counter medications or supplements for 6 months prior to the screening visit:
[0267] a. Compounds with androgenic or estrogenic properties (i.e., agonist or antagonist) or that affect production of sex hormones.
[0268] b. 5-a reductase inhibitors, e.g., finasteride and dutasteride.ATTORNEY DOCKET NO: 51835-010WO3
[0269] c. Fertility drugs, including clomiphene, FSH, human menopausal gonadotrophin (hMG) and human chorionic gonadotropin (hCG) preparations.
[0270] d. Growth hormone.
[0271] e. Opioid-receptor antagonists, e.g., naloxone and long-acting opioids.
[0272] f. Selective a-adrenergic-receptor antagonists (alpha blockers).
[0273] g. Topical or systemic testosterone replacement therapy (TRT).
[0274] h. Anabolic steroids.
[0275] 8. Weight loss or gain >5% body weight, or weight reduction surgery or procedure, within 3 months prior to the screening visit.
[0276] 9. Inability to reliably produce the required semen samples for trial assessments due to significant erectile dysfunction, anorgasmia, or other reasons.
[0277] 10. Participation in any clinical trial using clinical intervention within 3 months before the screening visit or 5 half-lives of investigational product administration, whichever is shorter.
[0278] 11. Any clinically significant 12-lead ECG abnormalities at screening, including QTc Fridericia interval >450 ms, or medical history of long QT syndrome.
[0279] 12. Known history of thromboembolic disease.
[0280] 13. Grade 3 lower extremity edema.
[0281] 14. Known cardiovascular disease meeting any of the following criteria:
[0282] a. Myocardial infarction or unstable angina within 6 months prior to the screening visit. b. Coronary artery bypass surgery, balloon angioplasty, percutaneous coronary intervention or carotid revascularization procedure within 6 months prior to the screening visit.
[0283] c. Uncontrolled hypertension within 3 months prior to the screening visit.
[0284] d. Significant cardiac arrhythmia within 6 months prior to the screening visit.
[0285] e. Endovascular procedure or surgical intervention for peripheral vascular disease within the 3 months prior to the screening visit.
[0286] f. Advanced ischemic heart disease within 6 months prior to the screening visit. g. Congestive heart failure (New York Heart Association [NYHA] lll / IV) within 6 months prior to the screening visit.
[0287] h. Stroke or transient ischemic attack within 6 months prior to the screening visit.
[0288] 15. Known history of osteoporosis or fragility fractures.
[0289] 16. Known moderate or severe impairment of renal or hepatic function, including stage 4 chronic kidney disease.
[0290] 17. Untreated diagnosis of sleep apnea (diagnosed in a sleep study).
[0291] 18. Any of the following laboratory parameters at the screening visit:
[0292] a. Hematocrit >50%.
[0293] b. Prolactin >2 times the ULN.
[0294] c. Abnormal thyroid-stimulating hormone (TSH) (outside reference range), unless reflex thyroxine (T4) and triiodothyronine (T3) testing is normal.ATTORNEY DOCKET NO: 51835-010WO3
[0295] d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >3 times the ULN or bilirubin >2 times the ULN (unless caused by Gilbert Syndrome).
[0296] e. Estimated glomerular filtration rate (eGFR) <60 mL / min (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] 2021 equationl).
[0297] f. HbA1 c >10% (>86 mmol / mol)
[0298] 19. History of cancer within the last 5 years, except for well-treated basal cell carcinoma, or cytotoxic chemotherapy at any time.
[0299] 20. Known alcohol and / or drug abuse within the last 12 months prior to randomization or evidence of such abuse indicated by the laboratory results during the screening assessments.
[0300] 21. Known chronic opioid use and / or misuse within the last 12 months prior to randomization 22. Any psychiatric or medical disorder or circumstance, which in the investigator’s opinion might jeopardize participant’s safety or compliance with the protocol.
[0301] 23. Hypersensitivity to any active ingredients or excipients in the medicinal products used in this trial.
[0302] Estimands
[0303] Primary Estimand
[0304] The primary clinical question of interest for the primary objective is whether a dose-response relationship exists between increasing doses of lef lutrozole (0.05, 0.1 , and 0.3 mg weekly) and TMSC. The primary endpoint estimand is defined according to the five attributes known in the art e.g., in Food and Drug Administration (FDA). ICH E9 (R1) Statistical principles for clinical trials: Addendum: Estimands and sensitivity analysis in clinical trials. (2021)., the disclosure of which is incorporated herein by reference.
[0305] • Treatment: Once weekly administration of leflutrozole 0.05 mg, leflutrozole 0.1 mg, leflutrozole 0.3 mg, or placebo.
[0306] • Population: A modified intention-to-treat (mITT) analysis set comprised of randomized and exposed participants who provide both at least one baseline semen sample and at least one end-of-treatment semen sample.
[0307] • Variable / Endpoint: Change from baseline to week 16 in average log-transformed TMSC.
[0308] Note: if only one semen sample is collected at screening that sample will constitute baseline.
[0309] • Intercurrent events: The following intercurrent events have been identified: 1) premature treatment discontinuation and 2) having no usable sample at baseline or week 16 due to reasons external to the participant (e.g., a handling or laboratory error).
[0310] • Population-level summary: The presence of a dose-response relationship as tested using the multiple comparison procedure-modeling (MCP-Mod) approach.
[0311] The first intercurrent event (premature treatment discontinuation) will be handled according to the treatment policy strategy. All available data will be used. The second intercurrent event will be handled according to the hypothetical strategy. Additional details regarding the implementation of these strategies are described in Primary Endpoint Analysis.ATTORNEY DOCKET NO: 51835-010WO3
[0312] The primary endpoint estimand will allow for the testing of multiple candidate dose-response curves under the MCP-Mod analysis framework. The choice of analysis population is appropriate for this phase 2b trial, guarantees the ability to estimate changes from baseline, and provides a basis for the reasonable assumption of missing at random for those observations that are missing due to the second intercurrent event.
[0313] Sensitivity Estimands
[0314] Sensitivity analyses will be performed that will require modifications to the primary endpoint estimand. The modifications are described using the impacted estimand attributes explained in the primary endpoint estimand above.
[0315] • Population: Two additional analysis sets will be used: 1) an intention-to-treat (ITT) analysis set comprised of all randomized participants and 2) a per protocol (PP) analysis set comprised of all participants in the mITT analysis set that do not have any protocol deviations deemed as impacting the primary endpoint.
[0316] • Variable / Endpoint: Two derivations of the TMSC endpoint will be used: 1 ) change from baseline to week 16 in average log-transformed TMSC (same as the primary endpoint) and 2) change from baseline to week 16 in maximum log-transformed TMSC. Note: if only one semen sample is collected at screening that sample will constitute baseline.
[0317] • Intercurrent events: The following intercurrent events have been identified for the sensitivity analyses: 1) premature treatment discontinuation, 2) having no usable sample at week 16 due to reasons external to the participant (e.g., a handling or laboratory error), and 3) having no usable sample at week 16 due to any other reason (relevant for the ITT analysis set only). Note that intercurrent events 1 and 2 are the same as the primary endpoint estimand and that intercurrent event 3 only applies when using the ITT analysis set.
[0318] Secondary Estimands
[0319] Secondary Estimand 1
[0320] The secondary estimand 1 will be used to estimate treatment effects as they are expected to be relevant for future pivotal trials. This estimand is very similar to the primary estimand with the exception of the population-level summary attribute.
[0321] • Population-level summary: LS mean differences between each active dose level (leflutrozole 0.05 mg, leflutrozole 0.1 mg, leflutrozole 0.3 mg) and placebo using an analysis of covariance (ANCOVA) model.
[0322] Intercurrent events will be handled according to the same strategies outlined for the primary endpoint estimand. Sensitivity analyses will be applied to secondary estimand 1 in the same manner as they were applied in the primary endpoint sensitivity estimands above. The modification to the population-level summary applies to all sensitivity analyses.ATTORNEY DOCKET NO: 51835-010WO3
[0323] Secondary Estimand 2
[0324] The secondary estimand 2 will be used to estimate treatment effects for dichotomous semen parameter endpoints. The modified attributes of this estimand are:
[0325] • Variable / Endpoint: Three endpoints are defined in this estimand: 1 ) an indicator of whether the week 16 TMSC values have met the pre-specified thresholds, 2) an indicator of whether the relative increases in week 16 TMSC values have met the pre-specified thresholds, and 3) an indicator whether the week 16 DFI values have met the pre-specified thresholds.
[0326] • Population-level summary: The odds ratio of achieving the threshold at week 16 for each active dose level (leflutrozole 0.05 mg, leflutrozole 0.1 mg, leflutrozole 0.3 mg) compared to placebo using a logistic regression model.
[0327] Intercurrent events will be handled according to the same strategies outlined for the primary endpoint estimand.
[0328] Secondary Estimand 3
[0329] The secondary estimand 3 will be used to estimate treatment effects for longitudinal dichotomous serum total testosterone parameter endpoints. The modified attributes of this estimand are:
[0330] • Population: Two analysis sets will be used: 1) an mITT analysis set comprised of randomized and exposed participants who provide both a baseline semen sample and an end-of- treatment semen sample, and 2) an ITT analysis set comprised of all randomized participants.
[0331] • Variable / Endpoint: An indicator of whether the serum total testosterone value is within the normal range (300-1000 ng / dL).
[0332] • Intercurrent events: The following intercurrent events have been identified: 1) premature treatment discontinuation, 2) having no usable sample at week 16 due to reasons external to the participant (e.g., a handling or laboratory error), and 3) missing data for any other reason.
[0333] • Population-level summary: LS mean differences between each active dose level (leflutrozole 0.05 mg, leflutrozole 0.1 mg, leflutrozole 0.3 mg) and placebo using a generalized estimated equations (GEE) model.
[0334] Intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made.
[0335] Secondary Estimand 4
[0336] The secondary estimand 4 will be used to estimate treatment effects for longitudinal continuous serum reproductive hormone parameter endpoints and longitudinal PROs (HIS-Q SF). The modified attributes of this estimand are:
[0337] Variable / Endpoint: Two endpoints are defined in this estimand: 1) changes from baseline to weeks 4, 8, 12, and 16 in serum reproductive hormone parameter levels, and 2) changes from baseline to weeks 4 and 16 in PROs (HIS-Q SF).ATTORNEY DOCKET NO: 51835-010WO3
[0338] • Intercurrent events: The following intercurrent events have been identified: 1) premature treatment discontinuation, 2) having no usable sample at week 16 due to reasons external to the participant (e.g., a handling or laboratory error), and 3) missing data for any other reason.
[0339] • Population-level summary: LS mean differences between each active dose level (leflutrozole 0.05 mg, leflutrozole 0.1 mg, leflutrozole 0.3 mg) and placebo using the mixed model repeated measures (MMRM) approach.
[0340] Intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made.
[0341] Secondary Estimand 5
[0342] The secondary estimand 5 will be used to estimate treatment effects for plasma leflutrozole concentrations. The modified attributes of this estimand are:
[0343] • Treatment: Once weekly administration of leflutrozole 0.05 mg, leflutrozole 0.1 mg, or leflutrozole 0.3 mg.
[0344] • Population: Two analysis sets will be used: 1) an mITT analysis set comprised of randomized and exposed participants who provide both a baseline semen sample and an end of treatment semen sample, and 2) a per protocol (PP) analysis set comprised of all participants in the mITT analysis set that do not have any protocol deviations deemed as impacting the primary endpoint.
[0345] • Variable / Endpoint: One endpoint is defined in this estimand: plasma leflutrozole concentrations at weeks 4, 8, 12, and 16.
[0346] • Population-level summary: LS mean differences between each active dose level (leflutrozole 0.05 mg, leflutrozole 0.1 mg, leflutrozole 0.3 mg) and the other active dose levels using the mixed model repeated measures (MMRM) approach.
[0347] Intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made.
[0348] Secondary Estimand 6
[0349] The secondary estimand 6 will be used to estimate treatment effects for semen leflutrozole concentrations. The modified attributes of this estimand are:
[0350] • Treatment: Once weekly administration of leflutrozole 0.05 mg, leflutrozole 0.1 mg, or leflutrozole 0.3 mg.
[0351] • Population: Two analysis sets will be used: 1) an mITT analysis set comprised of randomized and exposed participants who provide both a baseline semen sample and an end of treatment semen sample, and 2) a per protocol (PP) analysis set comprised of all participants in the mITT analysis set that do not have any protocol deviations deemed as impacting the primary endpoint.
[0352] • Variable / Endpoint: One endpoint is defined in this estimand: semen leflutrozole concentrations at week 12.ATTORNEY DOCKET NO: 51835-010WO3
[0353] • Population-level summary: LS mean differences between each active dose level (leflutrozole 0.05 mg, leflutrozole 0.1 mg, leflutrozole 0.3 mg) and the other active dose levels using an ANCOVA model.
[0354] Intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made.
[0355] Secondary Estimand 7
[0356] The secondary estimand 7 will be used to estimate treatment effects for the safety endpoint of overshooting testosterone. The modified attributes of this estimand are:
[0357] • Population: A safety analysis set comprised of randomized and exposed participants.
[0358] • Variable / Endpoint: An indicator of whether the serum total testosterone level has exceeded the pre-defined serum total testosterone threshold of 1500 ng / dL.
[0359] • Intercurrent events: The following intercurrent events have been identified: 1) premature treatment discontinuation, 2) having no usable sample at week 16 due to reasons external to the participant (e.g., a handling or laboratory error), and 3) missing data for any other reason.
[0360] • Population-level summary: LS mean differences between each active dose level (leflutrozole 0.05 mg, leflutrozole 0.1 mg, leflutrozole 0.3 mg) and placebo using a generalized estimated equations (GEE) model.
[0361] Intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made.
[0362] Statistical methods
[0363] Primary Endpoint Analysis
[0364] The primary objective is to evaluate the dose-response relationship of leflutrozole doses 0.05 mg weekly, 0.1 mg weekly and 0.3 mg weekly on semen quality. The primary endpoint is the change in TMSC after 16 weeks of treatment. Participants will be asked to provide one or two semen samples at screening and two semen samples at week 16. Thus, one or two values for TMSC are planned to be available for baseline, and two values for TMSC are planned to be available for week 16. TMSC will be log-transformed and if applicable the average log-transformed values at each time point will be used in the calculation of change from baseline to week 16.
[0365] Secondary Endpoint Analyses
[0366] Changes in Semen Parameters after 16 weeks of Treatment
[0367] A secondary objective is to evaluate the efficacy of leflutrozole on improving semen quality. Changes from baseline to week 16 will be measured for the semen parameters of TMSC, TSC, sperm concentration, sperm motility, normal sperm morphology, and semen volume. Similar to the primary endpoint, baseline values will be available from one or two semen samples collected at screening and week 16 values are planned to be available from two semen samples. Semen parameters will be log-transformed when appropriate and the average values at each time point when applicable will be used in the calculation of change from baseline to week 16.ATTORNEY DOCKET NO: 51835-010WO3
[0368] Percentage of Participants Meeting TMSC and DFI Thresholds
[0369] As part of the secondary objective to evaluate the efficacy of lef lutrozole on improving semen quality, participants will have their baseline and end-of-treatment TMSC and DFI levels assessed for meeting pre-defined thresholds. TMSC will be assessed for being at or above 5 million, 10 million, and 20 million. Further, TMSC will be assessed for having a relative increase of at least 50%, 75%, and 100%. DFI will be assessed for being below 15%, 25%, and 30%.
[0370] All variables will be summarized according to the presentation of categorical data.
[0371] Normalization of Serum Total Testosterone Levels
[0372] A secondary objective is to evaluate the efficacy of leflutrozole on normalizing serum total testosterone. Normal serum total testosterone levels are considered to be between 300-1000 ng / dL. For each participant at each visit, serum total testosterone will be determined to be normal or not normal.
[0373] The analysis will be performed in two ways. First, the proportion and associated 95% confidence interval of those achieving normalization will be estimated within each dose group at each time point. For the week 16 time point, this proportion and confidence interval will be compared to the important threshold of 75%.
[0374] Serum Concentrations of Reproductive Hormones
[0375] A secondary objective is to evaluate the changes in serum reproductive hormones associated with leflutrozole. The hormones to be evaluated at each visit are total testosterone, free testosterone, bioavailable testosterone, SHBG, FSH, LH, estradiol, inhibin B, and total testosterone / estradiol ratio.
[0376] The analysis of hormone parameters will be treated according to secondary endpoint estimand 4. The identified intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made. The analysis will be performed using the mITT, ITT, and PP analysis populations. All variables will be summarized according to the presentation of continuous data.
[0377] Plasma and Semen Concentrations of Leflutrozole
[0378] A secondary objective is to characterize the PK of leflutrozole in plasma and exposure in semen. An MMRM approach will be used to analyze the plasma leflutrozole concentrations. The response variable will be the changes from baseline in log-transformed serum leflutrozole concentrations. The model will include visit, treatment group, a visit-by-treatment group interaction, and the randomization stratification factor of baseline TMSC as covariates as well as a random intercept to account for multiple measurements on the same participants over time. An unstructured covariance matrix will be used and the Kenward-Roger approximation will be used to approximate the denominator degrees of freedom. Model simplification may be performed and the decision rules for doing so will be detailed in the SAP. For each visit, the LS mean and corresponding 95% confidence interval will be estimated for the treatment difference between each active dose of leflutrozoleATTORNEY DOCKET NO: 51835-010WO3
[0379] compared to the other active doses of leflutrozole. Additional population PK modeling may be performed and will be described in either the SAP or a separate PK SAP.
[0380] The analysis of plasma concentrations of leflutrozole will be treated according to secondary endpoint estimand 5. The identified intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made. The analysis will be performed using the mITT, ITT, and PP analysis populations. All variables will be summarized according to the presentation of continuous data.
[0381] The analysis of semen concentrations of leflutrozole will be treated according to secondary endpoint estimand 6. The identified intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made. The analysis will be performed using the mITT and PP analysis populations. All variables will be summarized according to the presentation of continuous data.
[0382] Hypogonadism Impact of Symptoms Questionnaire Short Form (HIS-Q SF)
[0383] A secondary objective is to evaluate the effect of leflutrozole on libido (sexual desire) and fatigue. The HIS-Q SF instrument will be used to assess this objective.
[0384] An MMRM approach will be used to analyze the HIS-Q SF. The response variable will be the score, total score, or domain score, as appropriate. The model will include visit, treatment group, a visit-by-treatment group interaction, the baseline value, and the randomization stratification factor of baseline TMSC as covariates as well as a random intercept to account for multiple measurements on the same participants over time. For each visit, the LS mean and corresponding 95% confidence interval will be estimated for the treatment difference between each active dose of leflutrozole compared to the placebo group.
[0385] The analysis of HIS-Q SF scores will be treated according to secondary endpoint estimand 4. The identified intercurrent events will be handled according to the treatment policy strategy. All available data will be used and no imputations will be made. The analysis will be performed using the mITT, ITT, and PP analysis populations. All variables will be summarized according to the presentation of continuous data. Additional categorical presentations may also be reported and will be described in the SAP.
[0386] Analysis of Exploratory Endpoints
[0387] The exploratory objectives of this trial include assessing the relationship between leflutrozole concentrations and BMI, serum reproductive hormone levels, and serum inflammatory markers. The relationship between serum reproductive hormone levels and semen parameters will also be assessed. In the event that there is a difference between TMSC and TPMSC or between participants with different BMI levels, additional statistical testing and dose-response modeling may be performed.
[0388] Correlations will be determined using Pearson’s correlation coefficient or, in the presence of non-normally distributed data, Spearman’s correlation. Statistical models will be used to describe more complex relationships between variables. Statistical models will be accompanied by line and / or dot plots. Additional modeling details for exploratory analyses will be described in the SAP.ATTORNEY DOCKET NO: 51835-010WO3
[0389] Adverse Events (AEs) Analyses
[0390] All AEs recorded for participants will be coded using MedDRA. The version of MedDRA will be documented. AEs will be grouped as follows:
[0391] • Pre-treatment AE: any AE occurring after signed informed consent and before start of IMP, or a pre-existing medical condition that worsens in intensity after signed informed consent but before start of IMP.
[0392] • Treatment-emergent AE (TEAE): any AE occurring after start of IMP and before the end-of- trial visit or a pre-treatment AE or pre-existing medical condition that worsens in intensity after start of IMP and before the end-of-trial visit.
[0393] TEAEs will be presented in summary tables and listings. Pre-treatment AEs will be presented in a listing only.
[0394] A TEAE overview summary table will be prepared including the number of participants reporting a TEAE, the percentage of participants with a TEAE, and the number of events reported. Summary tables will be prepared for the following categories:
[0395] • All TEAEs
[0396] • TEAEs by causality (reasonable possibility I no reasonable possibility)
[0397] • TEAEs leading to discontinuation
[0398] • TEAEs leading to death
[0399] • TEAEs by intensity
[0400] • Treatment-emergent adverse drug reactions by intensity
[0401] • Treatment-emergent serious adverse events
[0402] TEAEs will be tabulated by system organ class alphabetically and by MedDRA preferred term in decreasing order of frequency. The table will display the total number of participants reporting an AE, the percentage of participants with an AE, and the number of events reported. Summary tables will be prepared for the following:
[0403] • All TEAEs
[0404] • TEAEs by causality (reasonable possibility I no reasonable possibility)
[0405] • TEAEs leading to death
[0406] • TEAEs by intensity
[0407] • Treatment-emergent adverse drug reactions by intensity
[0408] • Treatment-emergent serious adverse events
[0409] • TEAEs with an incidence of >5% in any treatment group
[0410] • Non-serious TEAEs with an incidence of >5% in any treatment group
[0411] • TEAEs leading to discontinuation
[0412] In case of missing data for AEs, a worst-case approach or the most conservative approach will be used. If the intensity ofAE is missing, the AE will be regarded as “severe”; if the causal relationship to IMP is missing, the AE will be regarded as “reasonable possibility”; if seriousness is missing, the AE will be regarded as serious; if outcome is missing, and no date of outcome is present, the outcome is regarded as “not recovered”.ATTORNEY DOCKET NO: 51835-010WO3
[0413] Participants Who Overshoot Testosterone Levels
[0414] Participants will have their serum total testosterone levels measured over time and overshooting of testosterone will be determined as crossing the pre-defined threshold of 1500 ng / dL at any time during the trial.
[0415] Protocol Deviations
[0416] Protocol deviations determined to have potentially impacted the primary endpoint will be considered major and lead to exclusion of data from the PP analysis set. The identification of major protocol deviations will be made by sponsor’s medical and statistical representatives on the basis of a blinded review of data before declaration of clean file and lock of database.
[0417] Major protocol deviations will be summarized and listed by participant.
[0418] Example 2. Treatment of a patient diagnosed with male infertility resulting from hypogonadotropic hypogonadism by administration of leflutrozole
[0419] According to the methods disclosed herein, a physician of skill in the art can treat a subject diagnosed with male infertility resulting from hypogonadotropic hypogonadism so as to treat the underlying etiology of the male infertility. Male hypogonadism is a condition characterized by serum testosterone concentrations below the normal range for young, healthy men, with associated symptoms. Low testosterone production disrupts spermatogenesis, which is dependent on maintenance of high levels of intratesticular testosterone by the Leydig cells as well as of FSH stimulation of Sertoli cells. Male hypogonadotropic hypogonadism, and related diseases or conditions that may be treated by leflutrozole may be monitored by phenotypic metabolites or biomarkers that serve as observable indicators as to the effectiveness of a given treatment.
[0420] Leflutrozole treatment efficacy for male infertility can be measured by a variety of means, including but not limited to, sperm quality parameter such as total motile sperm count (TMSC), total sperm count (TSC), sperm concentration, sperm motility, normal sperm morphology, sperm DNA fragmentation index (DFI), and / or semen volume. Among the established parameters evaluated in semen, TMSC is a composite parameter of sperm concentration, motility and semen volume, which is considered an indicator of semen quality. Recent studies have underscored TMSC as a particularly reliable predictor of pregnancy in medically assisted reproduction, such as intrauterine insemination.
[0421] In addition, leflutrozole treatment efficacy for the underlying cause of infertility, namely male hypogonadotropic hypogonadism, can be measured by determining hormone levels associated with fertility, including but not limited to, changes in serum concentrations of total testosterone, free testosterone, bioavailable testosterone, sex hormone-binding globulin (SHBG), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, inhibin B, and total testosterone / estradiol ratio. These values may be assessed in comparison to the baseline measurements determined prior to treatment and at regular intervals throughout treatment e.g., 4, 8, 12, 16 weeks of treatment.
[0422] To treat the subject, a physician of skill in the art can administer to the subject a therapeutically effective amount of leflutrozole. In some embodiments, leflutrozole may be administered to the subject once weekly for 16 weeks. Leflutrozole may be administered to theATTORNEY DOCKET NO: 51835-010WO3
[0423] subject in an amount of from about 0.05 mg to about 0.5 mg per dose, such in an amount of about 0.05 mg, 0.1 mg, or 0.3 mg per dose.
[0424] Following administration of the composition to a patient, a practitioner of skill in the art can monitor the patient’s improvement in response to the therapy by a variety of methods. For example, a physician can monitor the changes in TMSC, DFI, TSC, sperm concentration, sperm motility, normal sperm morphology, and semen volume according to the World Health Organization (WHO) e.g., in WHO laboratory manual for the examination and processing of human semen. Sixth edition. Manual, (2021 ), the disclosure of which is incorporated herein by reference. A finding that the patient’s TMSC increases after 16 weeks (such as > 5 million, or > 50%) following administration of leflutrozole compared to test results prior to administration of leflutrozole indicates that the patient is responding favorably to the treatment. As a non-limiting example, a finding that the patient’s DFI decreases below a certain threshold (e.g., <10%, <15%, <25%, <30%, <35%, or <40%) 16 weeks following administration of leflutrozole indicates that the patient is responding favorably to the treatment.
[0425] Other Embodiments
[0426] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
[0427] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the invention that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.
[0428] Other embodiments are within the claims.
Claims
ATTORNEY DOCKET NO: 51835-010WO3CLAIMS1. A method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA.
2. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA.
3. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA.
4. A method of improving testicular function in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA.
5. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA.
6. A method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
7. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.ATTORNEY DOCKET NO: 51835-010WO38. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
9. A method of improving testicular function in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
10. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering.
11. A method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering, and wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
12. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volumeATTORNEY DOCKET NO: 51835-010WO3relative to a measurement of the same made prior to the administering, and wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
13. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering, and wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
14. A method of improving testicular function in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering, and wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
15. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (a) total sperm count, (b) sperm concentration, (c) sperm motility, (d) proportion of sperm exhibiting normal sperm morphology, and (e) semen volume relative to a measurement of the same made prior to the administering, and wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decreaseATTORNEY DOCKET NO: 51835-010WO3in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
16. A method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient maintains or improves sperm quality, wherein the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
17. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient maintains or improves sperm quality, wherein the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
18. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient maintains or improves sperm quality, wherein the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
19. A method of improving testicular function in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient maintains or improves sperm quality, wherein the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
20. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient maintains or improves sperm quality, wherein the sperm quality is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained fromATTORNEY DOCKET NO: 51835-010WO3the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
21. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in total motile sperm count (TMSC) relative to a measurement of the patient’s TMSC obtained prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
22. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in total sperm count relative to a measurement of the patient’s total sperm count obtained prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
23. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in sperm concentration relative to a measurement of the patient’s sperm concentration obtained prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
24. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuringATTORNEY DOCKET NO: 51835-010WO3an increase in sperm motility relative to a measurement of the patient’s sperm motility obtained prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
25. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in the percentage of sperm that have a normal sperm morphology relative to a measurement of the patient’s sperm morphology obtained prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
26. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality and maintains or improves sperm DNA integrity, wherein the improvement in sperm quality is assessed by measuring an increase in semen volume relative to a measurement of the patient’s semen volume obtained prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity.
27. A method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm quality as measured by a decrease in DNA fragmentation index (DFI).
28. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm DNA integrity as measured by a decrease in DNA fragmentation index (DFI).
29. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount ofATTORNEY DOCKET NO: 51835-010WO3leflutrozole, wherein following the administering, the patient exhibits an improvement in sperm DNA integrity as measured by a decrease in DNA fragmentation index (DFI).
30. A method of treating male infertility in a human patient in need thereof, the method comprising: a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
31. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
32. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
33. A method of improving testicular function in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i)ATTORNEY DOCKET NO: 51835-010WO3total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
34. A method of improving sperm quality in a human patient in need thereof, the method comprising: a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
35. A method of treating male infertility in a human patient in need thereof, the method comprising: a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
36. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of theATTORNEY DOCKET NO: 51835-010WO3DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
37. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
38. A method of improving testicular function in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibiting normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
39. A method of improving sperm quality in a human patient in need thereof, the method comprising: a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their sperm quality and integrity of sperm DNA and determining that the patient exhibits an improvement in sperm quality and maintains or improves integrity of sperm DNA, wherein the improvement in sperm quality is assessed by measuring an increase in one or more of (i) total sperm count, (ii) sperm concentration, (iii) sperm motility, (iv) proportion of sperm exhibitingATTORNEY DOCKET NO: 51835-010WO3normal sperm morphology, and (v) semen volume relative to a measurement of the same made prior to the administering, wherein the sperm DNA integrity is assessed by measuring a DNA fragmentation index (DFI) of a semen sample obtained from the patient following the administering, optionally wherein a finding of no change in the DFI or a decrease in the DFI relative to a measurement of the DFI of a semen sample obtained from the patient prior to the administering is taken as an indication of maintaining or improving sperm DNA integrity, respectively,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
40. A method of treating male infertility in a human patient in need thereof, the method comprising: a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
41. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
42. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
43. A method of improving testicular function in a human patient in need thereof, the method comprising:a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
44. A method of improving sperm quality in a human patient in need thereof, the method comprising:ATTORNEY DOCKET NO: 51835-010WO3a) periodically administering to the patient a therapeutically effective amount of leflutrozole, b) monitoring the patient for their DNA fragmentation index (DFI) in a semen sample obtained from the patient and determining that the patient maintains or exhibits a reduction in the DFI, relative to a measurement of the same made prior to the administering,c) continuing the periodic administration of a therapeutically effective amount of leflutrozole.
45. The method of any one of claims 11 -29 and 35-44, wherein the decrease in DNA fragmentation index (DFI) is 5% or greater.
46. The method of any one of claims 1 -45, wherein following administration the patient exhibits an improvement in sperm quality as measured by an increase in total motile sperm count (TMSC).
47. The method of claim 46, wherein the increase in TMSC is greater than 5 million.
48. The method of any one of claims 1 -5, 16-21 , 27-29, or 40-47, wherein following administration the patient exhibits an improvement in sperm quality as measured by any one of total sperm count, sperm concentration, sperm motility, normal sperm morphology, and semen volume.
49. The method of claim 48, wherein following administration the patient exhibits an improvement in sperm quality as measured by evaluating total sperm count.
50. The method of claim 48, wherein following administration the patient exhibits an improvement in sperm quality as measured by evaluating sperm concentration.
51. The method of claim 48, wherein following administration the patient exhibits an improvement in sperm quality as measured by evaluating sperm motility.
52. The method of claim 48, wherein following administration the patient exhibits an improvement in sperm quality as measured by evaluating sperm morphology.
53. The method of claim 48, wherein following administration the patient exhibits an improvement in sperm quality as measured by evaluating semen volume.
54. The method of any one of claims 1 -53, wherein following the administering, the patient exhibits a normalization of their total serum testosterone level, optionally wherein the normalization of the total serum testosterone level amounts to a total serum testosterone level of from about 300 ng / dL to about 1000 ng / dL.
55. The method of any one of the claims 1-54, wherein the patient has serum total testosterone concentration level below about 300 ng / dL prior to treatment.ATTORNEY DOCKET NO: 51835-010WO356. The method of any one of claims 1-55, wherein the therapeutically effective amount of leflutrozole is a dose ranging from about 0.025 mg to about 2.5 mg.
57. The method of any one of claims 1-56, wherein the therapeutically effective amount of leflutrozole is any one of 0.05 mg, 0.1 mg, and 0.3 mg per dose.
58. The method of any one of claims 1 -57, wherein the periodic administration comprises administering one dose of leflutrozole per week.
59. The method of any one of claims 1-58, wherein the therapeutically effective amount of leflutrozole is administered orally.
60. The method of any one of claims 1-59, wherein the therapeutically effective amount of leflutrozole is administered as a hard gelatine capsule.61 . The method of any one of claims 1 -60, wherein the patient has a total motile sperm count (TMSC) less than 20 million determined prior to treatment.
62. The method of claim 61 , wherein the patient has a total motile sperm count (TMSC) greater than 1 million determined prior to treatment.
63. The method of any one of the claims 1 -62 wherein the patient is an adult man aged 18-65 years.
64. The method of any one of the claims 1 -63, wherein the patient has a serum follicle stimulating hormone (FSH) level 1 -12 I U / L prior to treatment.
65. The method of any one of the claims 1 -64, wherein the patient has a serum SHGB level above the lower limit of normal (LLN) prior to treatment.
66. The method of any one of the claims 1 -65, wherein the patient has a serum estradiol (E2) level above the LLN prior to treatment.
67. The method of any one of the claims 1 -66, wherein the patient has a serum luteinizing hormone (LH) level below the LLN prior to treatment.
68. The method of any one of the claims 1 -67, wherein the patient does not have known history of osteoporosis or fragility fractures prior to treatment.ATTORNEY DOCKET NO: 51835-010WO369. The method of any one of the claims 1 -68, wherein the patient does not have known history of thromboembolic disease prior to treatment.
70. The method of any one of the claims 1-69, wherein the patient did not have myocardial infarction or unstable angina within 6 months prior to treatment.
71. The method of any one of the claims 1 -70, wherein the patient did not have coronary artery bypass surgery, balloon angioplasty, percutaneous coronary intervention or carotid revascularization procedure within 6 months prior to treatment.
72. The method of any one of the claims 1 -71 , wherein the patient did not have uncontrolled hypertension within 3 months prior to treatment.
73. The method of any one of the claims 1 -72, wherein the patient did not have significant cardiac arrhythmia within 6 months prior to treatment.
74. The method of any one of the claims 1-73, wherein the patient did not have advanced ischemic heart disease within 6 months prior to treatment.
75. The method of any one of the claims 1 -74, wherein the patient did not have stroke or transient ischemic attack within 6 months prior to treatment.
76. A method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in total motile sperm count (TMSC) as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.
77. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in TMSC as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.
78. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in TMSC as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.ATTORNEY DOCKET NO: 51835-010WO379. A method of improving testicular function in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in TMSC as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.
80. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein following the administering, the patient exhibits an increase in TMSC as compared to a measurement of the TMSC in a semen sample obtained from the patient prior to the administering.81 . The method of any one of claims 76-80, wherein the increase in TMSC is an increase of at least 1 .1-fold relative to the measurement of the TMSC in the semen sample obtained from the patient prior to the administering.
82. The method of any one of claims 76-80, wherein the increase in TMSC is an increase of from about 1 .1 -fold to about 5-fold relative to the measurement of the TMSC in the semen sample obtained from the patient prior to the administering.
83. The method of claim 82, wherein the increase in TMSC is an increase of about 1 .1 -fold, 1 .2-fold, 1 .3-fold , 1 .4-fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold , 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, .3.7-fold, 3.8-fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, or 5-fold relative to the measurement of the TMSC in the semen sample obtained from the patient prior to the administering.
84. The method of any one of claims 76-83, wherein following the administering, the patient exhibits a TMSC of at least about 2 x 107sperm cells.
85. The method of any one of claims 76-83, wherein following the administering, the patient exhibits a TMSC of from about 2 x 107sperm cells to about 1 x 108sperm cells.
86. The method of claim 85, wherein following the administering, the patient exhibits a TMSC of about 2 x 107sperm cells, 3 x 107sperm cells, 4 x 107sperm cells, 5 x 107sperm cells, 6 x 107sperm cells, 7 x 107sperm cells, 8 x 107sperm cells, 9 x 107sperm cells, or 1 x 108sperm cells.
87. The method of any one of claims 76-86, wherein following the administering, the patient exhibits an increase in sperm concentration relative to the measurement of the sperm concentration in the semen sample obtained from the patient prior to the administering, optionally wherein the increase in sperm concentration is an increase of from about 1 .1 -fold to about 5-fold relative to the measurement of the sperm concentration in the semen sample obtained from the patient prior to the administering.ATTORNEY DOCKET NO: 51835-010WO388. The method of claim 87, wherein the increase in sperm concentration is an increase of about 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, .3.7-fold, 3.8-fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, or 5-fold relative to the measurement of the sperm concentration in the semen sample obtained from the patient prior to the administering.
89. The method of any one of claims 76-88, wherein following the administering, the patient either maintains, or exhibits a decrease in, DNA fragmentation index (DFI) relative to a measurement of the DFI in a semen sample obtained from the patient prior to the administering.
90. The method of claim 89, wherein following the administering, the patient exhibits a decrease in DFI of from about 1% to about 5%, or greater, relative to a measurement of the DFI in a semen sample obtained from the patient prior to the administering.
91. The method of claim 90, wherein following the administering, the patient exhibits a decrease in DFI of 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, .2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5%, or more, relative to a measurement of the DFI in a semen sample obtained from the patient prior to the administering.
92. A method of treating male infertility in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
93. A method of treating a testosterone-dependent disease in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
94. A method of treating hypogonadotropic hypogonadism in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
95. A method of improving testicular function in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole,ATTORNEY DOCKET NO: 51835-010WO3wherein the patient is administered let lutrozole over the course of a treatment period of at least two months and / or no greater than six months.
96. A method of improving sperm quality in a human patient in need thereof, the method comprising periodically administering to the patient a therapeutically effective amount of leflutrozole, wherein the patient is administered leflutrozole over the course of a treatment period of at least two months and / or no greater than six months.
97. The method of any one of claims 92-96, wherein following the treatment period, the patient exhibits an increase in TMSC of at least 1 .1 -fold relative to a measurement of the TMSC in a semen sample obtained from the patient prior to the treatment period.
98. The method of any one of claims 92-96, wherein following the treatment period, the patient exhibits in TMSC of from about 1 .1 -fold to about 5-fold relative to a measurement of the TMSC in a semen sample obtained from the patient prior to the treatment period.
99. The method of claim 98, wherein the increase in TMSC is an increase of about 1 .1 -fold, 1 .2-fold, 1 .3-fold , 1 .4-fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold , 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, .3.7-fold, 3.8-fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, or 5-fold relative to the measurement of the TMSC in the semen sample obtained from the patient prior to the treatment period.
100. The method of any one of claims 92-99, wherein following the treatment period, the patient exhibits a TMSC of at least about 2 x 107sperm cells.101 . The method of any one of claims 92-100, wherein following the treatment period, the patient exhibits a TMSC of from about 2 x 107sperm cells to about 1 x 108sperm cells.
102. The method of claim 101 , wherein following the treatment period, the patient exhibits a TMSC of about 2 x 107sperm cells, 3 x 107sperm cells, 4 x 107sperm cells, 5 x 107sperm cells, 6 x 107sperm cells, 7 x 107sperm cells, 8 x 107sperm cells, 9 x 107sperm cells, or 1 x 108sperm cells.
103. The method of any one of claims 92-102, wherein following the treatment period, the patient exhibits an increase in sperm concentration relative to the measurement of the sperm concentration in a semen sample obtained from the patient prior to the treatment period, optionally wherein the increase in sperm concentration is an increase of from about 1 .1 -fold to about 5-fold relative to the measurement of the sperm concentration in the semen sample obtained from the patient prior to the treatment period.ATTORNEY DOCKET NO: 51835-010WO3104. The method of claim 103, wherein the increase in sperm concentration is an increase of about 1.1 -fold, 1.2-fold , 1.3-fold, 1.4-fold, 1.5-fold, 1 .6-fold , 1.7-fold, 1.8-fold, 1 .9-fold , 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, .3.7-fold, 3.8-fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, or 5-fold relative to the measurement of the sperm concentration in the semen sample obtained from the patient prior to the treatment period.
105. The method of any one of claims 92-104, wherein following the treatment period, the patient either maintains, or exhibits a decrease in, DNA fragmentation index (DFI) relative to a measurement of the DFI in a semen sample obtained from the patient prior to the treatment period.
106. The method of claim 105, wherein following the treatment period, the patient exhibits a decrease in DFI of from about 1% to about 5%, or greater, relative to a measurement of the DFI in a semen sample obtained from the patient prior to the treatment period.
107. The method of claim 106, wherein following the treatment period, the patient exhibits a decrease in DFI of 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1 .7%, 1.8%, 1.9%, .2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5%, or more, relative to a measurement of the DFI in a semen sample obtained from the patient prior to the treatment period.
108. The method of any one of claims 76-107, wherein following administration of the lef lutrozole, the patient exhibits an improvement in sperm quality as measured by evaluating sperm motility.
109. The method of any one of claims 76-108, wherein following administration of the lef lutrozole, the patient exhibits an improvement in sperm quality as measured by evaluating sperm morphology.
110. The method of any one of claims 76-109, wherein following administration of the lef I utrozole , the patient exhibits an improvement in sperm quality as measured by evaluating semen volume.
111. The method of any one of claims 76-110, wherein following administration of the lef I utrozole , the patient exhibits a normalization of their total serum testosterone level, optionally wherein the normalization of the total serum testosterone level amounts to a total serum testosterone level of from about 300 ng / dL to about 1000 ng / dL.
112. The method of any one of the claims 76-111 , wherein the patient has serum total testosterone concentration level below about 300 ng / dL prior to treatment.
113. The method of any one of claims 76-112, wherein the therapeutically effective amount of leflutrozole is a dose ranging from about 0.025 mg to about 2.5 mg.ATTORNEY DOCKET NO: 51835-010WO3114. The method of any one of claims 76-113, wherein the therapeutically effective amount of leflutrozole is any one of 0.05 mg, 0.1 mg, and 0.3 mg per dose.
115. The method of any one of claims 76-114, wherein the periodic administration of leflutrozole comprises administering one dose of leflutrozole per week.
116. The method of any one of claims 76-115, wherein the therapeutically effective amount of leflutrozole is administered orally.
117. The method of any one of claims 76-116, wherein the therapeutically effective amount of leflutrozole is administered in the form of a hard gelatine capsule.
118. The method of any one of claims 76-117, wherein the patient has a TMSC of less than 20 million determined prior to treatment.
119. The method of claim 118, wherein the patient has a TMSC of greater than 1 million determined prior to treatment.
120. The method of any one of the claims 76-119, wherein the patient is an adult man aged 18-65 years.
121. The method of any one of the claims 76-120, wherein the patient has a serum follicle stimulating hormone (FSH) level 1 -12 I U / L prior to administration of the leflutrozole.
122. The method of any one of the claims 76-121 , wherein the patient has a serum SHGB level above the lower limit of normal (LLN) prior to administration of the leflutrozole.
123. The method of any one of the claims 76-122, wherein the patient has a serum estradiol (E2) level above the LLN prior to administration of the leflutrozole.
124. The method of any one of the claims 76-123, wherein the patient has a serum luteinizing hormone (LH) level below the LLN prior to administration of the leflutrozole.
125. The method of any one of claims 92-124, wherein the treatment period has a duration of at least two months.
126. The method of claim 125, wherein the treatment period has a duration of at least three months.
127. The method of claim 126, wherein the treatment period has a duration of at least four months.ATTORNEY DOCKET NO: 51835-010WO3128. The method of claim 127, wherein the treatment period has a duration of at least five months.
129. The method of any one of claims 92-128, wherein the treatment period has a duration of at most six months or 24 weeks.
130. The method of any one of claims 92-124, wherein the treatment period has a duration of from about 4 weeks to about 24 weeks.
131. The method of claim 130, wherein the treatment period has a duration of about 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, or 24 weeks.
